roche finance report roche finance report fhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom table content roche group noncurrent liability finance brief debt finance brief equity attributable roche financial review shareholder roche group consolidate financial earning share statement nonvoting equity security note roche group consolidate noncontrolle interest financial statement statement cash flow summary significant accounting risk management policy relate party operate segment information subsidiary associate genentech report roche management chugai internal control financial report financial income financing cost report statutory auditor income taxis consolidate financial statement business combination report independent auditor global restructuring plan internal control financial reporting employee benefit multiyear overview supplementary pension postemployment information benefit roche security employee stock option equity compensation plan property plant equipment roche holding ltd basel goodwill financial statement intangible asset note financial statement associate summary significant accounting financial longterm asset policy inventory equity account receivable contingent liability current asset significant shareholder marketable security risk management cash cash equivalent board executive remuneration account payable board executive shareholding accrue current liability appropriation available earning derivative financial instrument report statutory auditor provision contingent liability financial statement roche finance report roche group finance brief finance brief key result local sale growth core operating profit margin sale pharmaceutical diagnostic group change sales mchf mchf chf sales research development core operating profit operating profit operate free cash flow net income net income attributable roche shareholder free cash flow core eps chf diluted eps chf dividend share chf december december change chf net cash debt capitalisation debt equity page definition core ep propose board director local currency finance leadership team erich hunziker chief financial officer peter eisenre tax insurance christian hebich diagnostic finance andreas knierzinger treasury karl mahler investor relations patrick mongrolle pharma medicine finance erwin schneider control accounting nigel sheail business development petra storsberg pre finance finance brief roche finance report finance brief sale group sale billion swiss franc decline large pandemic sale tamiflu comparative period currency translation effect strength swiss franc relative dollar euro local currency sale stable growth underlie business compensate sharply reduce tamiflu sale exclude tamiflu group sale increase local currency pharmaceutical division sale grow market local currency exclude tamiflu solid growth key oncology product lucentis ophthalmology actemraroactemra rheumatoid arthritis tamiflu sale decline sharply billion swiss franc billion swiss franc pandemic influenza virus swine flu outbreak healthcare reform united states austerity measure europe price cut japan negative impact pharmaceutical sale million swiss franc percentage point sale growth diagnostic sale increase local currency billion swiss franc drive sale growth professional diagnostic diabetes care significantly ahead estimate ivd market growth rate operating result core operating profit increase local currency billion swiss franc thank genentech integration synergies productivity improvement offset substantially low profit contribution tamiflu impact healthcare reform core operating profit margin increase percentage point increase pharmaceutical division percentage point diagnostic division percentage point research development expenditure core basis decline local currency billion swiss franc represent group sale november group announce details operational excellence programme initial restructuring charge billion swiss franc include ifrs operating result mainly relate severance cost asset impairment treasury core net financial expense increase million swiss franc primarily year financing cost debt issue quarter respect genentech transaction loss early redemption debt repayment debt ahead schedule billion dollar debt redeem early september billion swiss franc bond note issue finance genentech transaction repay end billion dollar call early redemption march financial condition strong financial condition operate free cash flow billion swiss franc free cash flow billion swiss franc net debt position billion swiss franc december billion billion swiss franc previous yearend strong credit rating moodys standard poor net income core eps net income increase billion swiss franc compare primarily drive strong operating result genentech transaction accretive impact net income attributable roche shareholder rise billion swiss franc synergies elimination noncontrolle interest compensate cost finance transaction core ep high constant exchange rate high swiss franc shareholder return increase propose dividend swiss franc represent consecutive year dividend growth approve shareholder result increase payout ratio high dividend yield roche share nonvoting equity security base yearend price decline total shareholder return tsr share price movement plus dividend combine performance share nonvoting equity security roche finance report roche group financial review roche group financial review group operating result sale billion chf core operating profit billion chf growth sale group achieve solid operating performance sale stable local currency swiss franc dollar billion swiss franc underlie growth able compensate expect decline tamiflu sale initial impact healthcare reform austerity measure exclude tamiflu sale increase local currency pharmaceutical division represent group sale diagnostic division contribute sale pharmaceutical division decline local currency billion swiss franc exclude tamiflu local growth market growth demand oncology drug avastin mabthera rituxan herceptin xeloda tarceva continue grow strongly additional major growth driver lucentis ophthalmology actemraroactemra rheumatoid arthritis mircera renal anemia positive factor offset expect decline tamiflu sale reduction cellcept sale patent expiry impact healthcare reform european austerity measure price cut japan diagnostic division increase sale billion swiss franc grow local currency swiss franc dollar strengthen lead market position major growth area professional diagnostic diabete care group expand presentation core result previously core ep show income statement group operating result division show ifrs core basis allow transparent assessment actual result underlie performance business core concept fully describe page reconciliation ifrs core result give core basis group operating profit increase local currency swiss franc sale stable increase profitability drive synergies genentech integration productivity improvement cost containment performance achieve spite substantially low contribution tamiflu impact healthcare reform marketing distribution cost remain prior year level local currency research development cost decline pharmaceutical division increase core operating profit local currency drive primarily cost synergies genentech integration resource prioritisation productivity improvement core operate profit growth diagnostic division local currency mainly result sale growth ongoing operational efficiency programme group core operating profit margin increase percentage point pharmaceutical division improve percentage point diagnostic division percentage point margin increase group level low division mix effect strong growth relatively lowermargin diagnostic business shift certain administration activity pharmaceutical division corporate result new group organisation effective january group operate free cash flow remain strongly positive billion swiss franc decrease local currency swiss franc principally arise payment early certain large yearend accrue liability notably tamiflu royalty employee retentionseverance scheme free cash flow decrease billion swiss franc billion swiss franc primarily nonrecurrence onetime tax benefit billion swiss franc follow genentech transaction interest payment new debt issue fund genentech transaction comparable payment high dividend payment group continue pay debt issue half finance genentech transaction november group announce details operational excellence programme consequence implement respective restructuring measure significant cost incur cost recognise billion swiss franc mainly relate severance payment follow reduction position sale marketing global manufacturing global development research early development impairment intangible asset pharmaceutical division account billion swiss franc cost billion swiss franc relate diagnostic division roughly charge noncash impairment property plant equipment intangible asset pharmaceutical division complete integration restructuring activity genentech expense million swiss franc incur mainly site closure employeerelate cost comparative period million swiss franc incur mainly impairment manufacturing facility divisional operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale roche finance report roche group financial review divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase local currency core operate profit increase local currency margin percentage point increase operate profit increase local currency margin percentage point increase operate free cash flow increase local currency margin percentage point increase pharmaceutical operating result sale pharmaceutical division decline local currency billion swiss franc exclude tamiflu local growth market growth core operating profit grow local currency stable swiss franc billion swiss franc core operating profit margin increase percentage point drive genentech integration synergy resource prioritisation productivity improvement achieve spite expect sharp decline tamiflu sale billion swiss franc impact healthcare reform austerity measure exchange rate movement negative percentage point effect margin marketing effort focus grow oncology rheumatoid arthritis portfolio especially broad indication avastin herceptin launch actemraroactemra marketing distribution cost local currency decrease tight cost management cover increase allowance bad debt southern europe research development cost reduce constant exchange rate previous year increase significantly achieve resource prioritisation secure longterm growth rich pipeline pharmaceutical division acquire biopharmaceutical company marcadia biotech research programme focus new peptide therapie treatment type diabete obesity pharmaceutical division incur noncore expense billion swiss franc relate operational excellence programme billion swiss franc relate termination cost show global restructuring cost reconciliation core result remain billion swiss franc consist impairment intangible asset include global restructuring cost remain cost billion swiss franc genentech integration restructuring pharmaceutical division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale operate profit margin sale operate free cash flow margin sale sale sale therapeutic area major growth driver key product oncology ophthalmology inflammationautoimmunetransplantation therapeutic area virology sale tamiflu decrease substantially unusually high sale arise influenza virus swine flu sale inflammationautoimmunetransplantation increase slightly continued success mabthera rituxan rheumatoid arthritis excellent uptake actemraroactemra compensate negative impact cellcept patent expiry united states sale renal anemia therapeutic area decrease increasingly competitive costsensitive market pharmaceutical division sale therapeutic area sale change therapeutic area mchf sale local currency oncology virology inflammationautoimmunetransplantation metabolismbone ophthalmology renal anemia total sale product pharmaceutical product represent sale pharmaceutical portfolio decline local currency growth contribution majority product entirely offset expect significant decline tamiflu sale billion swiss franc local sale growth pharmaceutical division primarily drive product avastin mabtherarituxan herceptin lucentis actemraroactemra xeloda product represent portfolio generate billion swiss franc additional sale compare sale product decline contribution sale growth renal anemia medication mircera fully offset low sale product generic erosion follow patent expiry voluntary withdrawal raptiva market roche finance report roche group financial review pharmaceutical division sale product sale change product mchf sale local currency franchise avastin oncology mabtherarituxan oncologyiat herceptin oncology pegasys virology lucentis ophthalmology xeloda oncology tarceva oncology cellcept iat neorecormonepogin renal anemia oncology bonvivaboniva metabolismbone tamiflu virology xolair respiratory disease valcytecymevene virology pulmozyme respiratory disease activasetnkase cardiovascular disease nutropin metabolismbone actemraroactemra iat xenical metabolismbone neutrogin oncology rocephin infectious disease total product product total inflammationautoimmunetransplantation avastin sale advance colorectal breast lung kidney cancer relapse glioblastoma type brain tumour rise local currency billion swiss franc reflect continued positive uptake product overall sale growth western europe drive primarily continue uptake breast cancer improve uptake lung cancer sale stable overall low sale second half reflect regulatory reimbursement uncertainty metastatic breast cancer indication strong sale growth japan drive good uptake colorectal cancer nonsmall cell lung cancer significant sale growth record latin america follow marketing approval china early year avastin launch firstline treatment metastatic colorectal cancer quarter contribute sharp growth sale asia mabtherarituxan fullyear sale oncology autoimmune disease area nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis total billion swiss franc increase local currency versus sustained growth oncology segment drive uptake cll continue strong use nhl western europe high growth international region include increase key emerge market reflect uptake medicine nhl indication european rollout mabthera new indication firstline maintenance treatment patient follicular lymphoma begin fourth quarter estimate sale segment reach billion swiss franc mark growth drive increase use patient inadequate response tumour necrosis factor inhibitor grow acceptance month repeat treatment interval herceptin global sale herpositive breast cancer advance herpositive stomach cancer rise local currency billion swiss franc sustained growth united states western europe significant increase international region herceptin maintain solid market penetration breast cancer sale benefit initial uptake stomach cancer country market addition improvement quality testing expand population patient eligible treatment herceptin high sale volume japan outweigh effect revise reimbursement price april result significant decline sale compare pegasys sale hepatitis remain virtually stable yearonyear billion swiss franc growth see asia region sale decrease western europe japan offset growth international region especially asia cemai country product market share continue expand main european market japan global sale continue benefit clinical datum reinforce superiority pegasys hepatitis treatment option increase use treatment hepatitis lucentis sale wet agerelate macular degeneration macular edema follow retinal vein occlusion grow local currency billion swiss franc strong growth year drive primarily increase total number patient receive lucentis time patient treatment launch lucentis treatment macular edema swell retina follow retinal vein occlusion begin late june initial uptake encourage xeloda sale colorectal stomach breast cancer rise local currency billion swiss franc growth drive primarily significant increase united states japan china product large market global sale xeloda benefit number new indication include stomach cancer china expand metastatic colorectal cancer indication japan adjuvant colon cancer europe increase patient share metastatic breast cancer tarceva sale advanced lung pancreatic cancer grow local currency billion swiss franc drive mainly increase use secondline nonsmall cell lung cancer set main growth contribution come international region growth japan united states growth reflect steady demand lung pancreatic cancer indication impact government healthcare reform background stable demand sale western europe decline slightly mainly result governmentmandate pharmaceutical price reduction rebate major market sustain sale growth japan reflect continue market penetration oncologist increase confidence benefit treatment tarceva cellcept billion swiss franc sale cellcept prevention solid organ transplant rejection remain significant sale decrease local currency loss patent exclusivity united states result loss competition generic version cause sale decrease partly offset sale growth international region japan neorecormonepogin combine sale roche neorecormon chugais epogin epoetin beta decline local currency billion swiss franc roche overall share european anemia market remain stable despite increase biosimilar competition mainly strong performance mircera major country robust market share volume neorecormon renal indication decline sale epogin japan mainly competition dialysis market low national health insurance reimbursement price effect outweigh increase demand medicine predialysis segment roche finance report roche group financial review tamiflu follow unprecedented demand influenza pandemic sale tamiflu influenza total billion swiss franc decrease billion swiss franc low government stockpile order largely complete early influenza pandemic pass peak sale fall sharply quarter sale affect relatively mild influenza season hemisphere actemraroactemra global rollout novel rheumatoid arthritis medicine actemra continue sale total million swiss franc rise local currency uptake actemraroactemra united states launch market remain encourage continued strong sale growth japan reflect increase use actemra firstline biologic mircera sale renal anemia medication mircera rise local currency million swiss franc demand mircera available country worldwide come mainly predialysis segment new patient commencement business report annual report information roche pharmaceutical product sale region worldwide pandemic influenza virus swine flu outbreak begin half pandemic sale result unusually high sale tamiflu comparative period significant decline demand december lead vary impact region show table follow comment focus business exclude tamiflu united states sale continue grow local currency drive oncology product lucentis cover substantial decline cellcept post patent expiry dollar negative impact regional sale growth percentage point addition initial impact healthcare reform lead reduction sale approximately million dollar million swiss franc increase rebate affect major product sale western europe increase strong oncology portfolio good uptake actemraroactemra mircera spite estimate million swiss franc negative impact european austerity measure cemai central eastern europe middle east africa central asia indian subcontinent latin america asiapacific region show strong growth drive mabtherarituxan herceptin avastin xeloda pegasys mircera sale japan increase continued success avastin actemraroactemra xeloda tarceva mabthera outweigh impact biennial price cut japan effective april pharmaceutical division sale region change sale change exclude tamiflu region mchf sale local currency local currency united states western europe japan cemai latin america asiapacific region total central eastern europe middle east africa central asia indian subcontinent operating result royalty operating income decline local currency particular million swiss franc low income outlicense agreement decrease mainly nonrecurrence significant milestone payment glaxosmithkline million swiss franc relate orlistat otc approval million swiss francs bonvivaboniva milestone income chugai furthermore comparative period include income disposal product mainly latin america million swiss franc compare million swiss franc effect partly offset high royalty income total royalty operating income percentage sale decrease percentage point pharmaceutical division royalty operating income change mchf mchf local currency royalty income income outlicense agreement income disposal product total ifrs core basis cost sale core basis cost decrease local currency result low royalty expense reduction manufacturing cost low cost collaboration agreement percentage sale cost sale decline decline manufacturing cost good sell period cost mainly productivity improvement favourable product mix effect comparative period include onetime impact inventory writeoff million swiss franc voluntary withdrawal raptiva market royalty expense low mainly low sale tamiflu cellcept partly offset high royalty bonvivaboniva million swiss franc result contractual change glaxosmithkline expense collaboration profitshare agreement decrease reduction primarily result amend agreement glaxosmithkline bonvivaboniva expense million swiss franc compare million swiss franc expense collaboration agreement biogen idec novartis osi increase million swiss franc million swiss franc project termination cost manufacture logistic area million swiss franc record operational excellence programme amortisation charge market product use low local currency certain acquisition intangible fully amortise end pharmaceutical division cost sale change mchf mchf local currency manufacturing cost good sell period cost royalty expense collaboration profitshare agreement restructuring expense impairment property plant equipment cost sale core basis global restructure operational excellence amortisation intangible asset total ifrs basis roche finance report roche group financial review marketing distribution core cost decline local currency billion swiss franc percentage sale remain practically stable sale marketing effort focusse oncology portfolio rollout additional approve indication avastin herceptin continue rollout support actemraroactemra rheumatoid arthritis bonvivaboniva pegasys increase focus emerge market bad debt provision increase significantly take account financial crisis particularly southern europe high cost compensate generally low product promotion field force expense termination cost commercial operation million swiss franc record operational excellence programme pharmaceutical division marketing distribution change mchf mchf local currency marketing distribution core basis global restructure operational excellence total ifrs basis research development increase research development cost see previous year halt core research development expense decline local currency resource prioritisation secure longterm growth promise pipeline research development cost percentage sale main focus area metabolism franchise new phase iii initiation require small study investment earlierstage neurology portfolio offset low life cycle investment oncology inflammation research development expense include immediate recognition remain cost million swiss franc necessary cover termination ocrelizumab rheumatoid arthritis development programme payment receive novartis opt lucentis study treatment macular edema follow retinal vein occlusion majority cost million swiss franc record operational excellence programme relate impairment intangible asset project termination million swiss franc termination cost research development million swiss franc remain impairment charge million swiss franc include million swiss franc respect product intangible available use primarily recent clinical datum pharmaceutical division research development change mchf mchf local currency research development core basis global restructure operational excellence amortisation intangible asset impairment intangible asset total ifrs basis general administration overall core cost decrease local currency drive low administration cost organisational shift effective january certain finance communication function corporate administration cost million swiss franc percentage point sale function include result pharmaceutical division remain reduction administration cost mainly synergy follow genentech integration noncore cost general administration area include cost million swiss franc relate operational excellence consist mainly employee termination cost effective march group obtain ownership genentech continue implementation reorganisation group pharmaceuticals business announce july subsequently group commence restructuring pharmaceutical manufacturing operation particularly biotech network expense million swiss franc incur mainly site closure employeerelate cost comparative period million swiss franc incur mainly impairment manufacturing facility additional information give note consolidated financial statement total cost integration restructure billion swiss franc include billion swiss franc incur year total billion swiss franc approximately billion swiss franc noncash legal environmental settlement cost million swiss franc decrease million swiss franc compare cost represent current development litigation issue additional information give note consolidated financial statement pharmaceutical division general administration change mchf mchf local currency administration gain loss divestment business restructure expense gain loss disposal property plant equipment general item general administration core basis global restructure operational excellence global restructure genentech transaction alliance business combination legal environmental settlement total ifrs basis operate free cash flow pharmaceutical division generate strong operating free cash flow billion swiss franc percentage sale division operate free cash flow decrease compare decrease local currency compare drive increase net work capital billion swiss franc mainly payment large yearend accrual include payment employee retentionseverance scheme high royalty payment relate large tamiflu sale second half thirdparty receivable remain end similar level despite high dayssalesoutstande level particularly southern europe operate profit cash adjustment decrease mainly billion swiss franc impairment property plant equipment follow genentech transaction comparative period roche finance report roche group financial review pharmaceutical division operate free cash flow mchf mchf operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment increase decrease net work capital account receivable inventory account payable total increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale operate profit cash adjustment include elimination depreciation amortisation impairment charge property plant equipment intangible asset replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent detail breakdown provide diagnostic operating result diagnostic division increase sale billion swiss franc grow local currency swiss franc dollar strengthen lead market position core operating profit increase local currency swiss franc billion swiss franc core operating profit margin increase percentage point sale drive high sale growth positive effect favourable product mix manufacturing efficiency gain tight management operating expense exchange rate movement positive percentage point effect margin global restructuring expense million swiss franc record operational excellence development manufacturing activity relate blood gas diagnostic transfer rotkreuz switzerland division professional diagnostic business area global headquarters site graz austria close research development insulin pump transfer burgdorf switzerland mannheim germany diabete care global headquarters addition manufacture new pump outsource burgdorf site close diagnostic chemical raw material manufacture analytical service germany discontinue mannheim transfer site diagnostic division acquire micropump specialist medingo broaden portfolio innovative insulin delivery technology strengthen position diabetes care business tissue diagnostic business area complete acquisition company bioimagene complement strengthen offer image analysis information management information divisional business pipeline business report annual report diagnostic division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale operate profit margin sale operate free cash flow margin sale sale diagnostic business continue increase sale significantly ivd market growth local currency professional diagnostic sale growth leverage immuno diagnostic diabetes care sale growth main growth contributor business area grow respective market sale molecular diagnostic total million swiss franc increase lead virology segment apply science sale grow local currency drive cell analysis genomic custom biotech segment sale tissue diagnostic total million swiss franc drive sale advanced tissue stain market diagnostic division sale business area sale change business area mchf sale local currency professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic total professional diagnostic sale rise local currency twice market rate million swiss franc immunoassay business grew gain additional market share new placement cobas analyser combine strong assay sale expand test menu key driver clinical chemistry growth pointofcare solution growth professional diagnostic launch new nextgeneration immunoassay include test diagnose monitor infectious disease follow fda approval september rollout cobas series clinical chemistry module cobas cobas commence july new cobas immunoassay module launch europe country recognise mark october module improve test efficiency enable largevolume laboratory fully consolidate immunoassay clinical chemistry test roche finance report roche group financial review diabetes care combine sale blood glucose monitoring system insulin pump outpace market rise local currency million swiss franc main growth driver accuchek avivaaccuchek performa blood glucose monitoring system support continued market uptake accuchek aviva nanoaccuchek performa nano meter stripfree accuchek mobile system maltoseindependent test strip chemistry receive regulatory approval june immediately roll japanese regulatory approval maltosefree test strip chemistry expect enable late addition accuchek portfolio launch key market insulin delivery business post robust sale growth primarily accuchek combo combine insulin pump blood glucose monitoring system diabete care acquire medingo enhance portfolio innovative micropump strengthen offer insulin delivery molecular diagnostic sale local currency increase million swiss franc main contribution virology eastern europe north america asiapacific demand continue fully automate cobas system mid highthroughput laboratory fda approve lightcycler mrsa advanced test dual pcrtarget hiv test successfully launch molecular diagnostic receive mark certification cobas taqscreen dpx test duplex test enable simultaneous realtime detection parvovirus hepatitis virus increase safety human plasma plasma product datum athena trial assess utility cobas hpv test screen cervical cancer present international papillomavirus conference july data confirm increase accuracy hpv dna testing include genotype file test fda june apply science sale rise local currency million swiss franc drive strong growth cell analysis genomic custom biotech segment sale magna pure lightcycler product line sample preparation quantitative pcr analysis decline dramatically low demand influenza virus testing cell analysis drive integration innovatis product portfolio continue demand xcelligence system include recently launch rtca instrument highthroughput analysis rtca cardio instrument labelfree cardiotoxicity testing genomic uptake mediumthroughput benchtop junior dna sequencer strong enable nextgeneration sequence thousand research labs worldwide apply science enter partnership ibm develop thirdgeneration sequence nanoporebase singlemolecule sequence tissue diagnostic sale total million swiss franc local currency outperform market key region advance tissue stain immunohistochemistry ihc situ hybridisation ish continue main growth driver reflect strong reagent sale continue robust uptake benchmark ultra system simultaneous ihc ish test single platform tissue diagnostic expand advanced staining portfolio launch new antibody support diagnosis cancer september label sish dna probe extend europe country recognise mark include use assess likelihood response treatment herceptin breast gastric cancer tissue diagnostic complete acquisition bioimagene leader digital pathology analysis workflow product enable high resolution wholeslide digital image glass microscope slide business report annual report information roche diagnostic product business area sale region sale outgrow market region asiapacific country lead china south korea achieve especially strong growth drive mainly professional diagnostic despite pricing challenge sale growth outperform market emea europe middle east africa mature emerge economy drive strong performance professional diagnostic diabetes care business area professional diagnostic tissue diagnostic primary growth driver north america growth japan good performance professional diagnostic offset continue challenge diabetes care overall divisional sale grow ahead market increase investment region high demand immunoassay leadingedge roche product contribute robust abovemarket growth brazil russia india china south korea mexico turkey emerge market sale accounting total divisional sale diagnostic division sale region sale change region mchf sale local currency emea north america asiapacific latin america japan total europe middle east africa operating result royalty operating income income million swiss franc high local currency compare local currency increase outlicense income result new pcr license contract increase royalty income diagnostic division royalty operating income change mchf mchf local currency royalty income income outlicense agreement income disposal product total ifrs core basis cost sale core cost sale increase local currency growth proportional sale growth result low cost sale ratio compare cost reduction initiative centralisation logistic service harmonisation technical service practice renegotiation supplier contract positive impact compensate high depreciation installation cost continue investment expand market share meter placement increase instal instrument base operational excellence programme cost million swiss franc incur relate manufacturing facility graz austria rotkreuz burgdorf switzerland mannheim germany total cost sale increase compare roche finance report roche group financial review diagnostic division cost sale change mchf mchf local currency manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructure operational excellence amortisation product intangible impairment product intangible total ifrs basis marketing distribution division introduce major new product initial market increase local currency mainly reflect high cost professional diagnostic tissue diagnostic strong investment emea asiapacific accelerate growth tissue diagnostic core basis marketing distribution cost percentage sale compare expense million swiss franc incur relate operational excellence marketing distribution diagnostic division marketing distribution change mchf mchf local currency marketing distribution core basis global restructure operational excellence amortisation intangible asset total ifrs basis research development core cost decline local currency result tight cost control particular professional diagnostic apply science molecular diagnostic percentage sale research development cost decrease major programme include athena hpv trial development maltose independent chemistry blood glucose meter expense million swiss franc incur relate operational excellence research development describe graz austria rotkreuz burgdorf switzerland diagnostic division research development change mchf mchf local currency research development core basis global restructure operational excellence amortisation intangible asset impairment intangible asset total ifrs basis general administration core general administration cost decrease local currency low restructuring expense percentage sale cost decline percentage point diagnostic division general administration change mchf mchf local currency administration restructuring expense gain loss disposal property plant equipment general item general administration core basis global restructure operational excellence alliance business combination legal environmental settlement total ifrs basis operate free cash flow operate free cash flow diagnostic division million swiss franc increase local currency compare strong increase operating profit partially offset increase net work capital increase net work capital million swiss franc primarily increase account receivable especially certain european country greece high inventory level result launch key product percentage sale operate free cash flow diagnostic division increase compare diagnostic division operate free cash flow mchf mchf operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment increase decrease net work capital account receivable inventory account payable total increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale operate profit cash adjustment include elimination depreciation amortisation impairment charge property plant equipment intangible asset replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent detail breakdown provide roche finance report roche group financial review corporate operating cost general administration core basis cost high local currency million swiss franc million swiss franc mainly new group organisation effective january begin administration cost include certain finance communication function previously pharmaceutical division cost million swiss franc operate free cash flow net outflow million swiss franc net outflow million swiss franc drive high operating expense total cost ifrs basis grow local currency million swiss franc million swiss franc low rate core cost operational excellence restructuring expense million swiss franc significantly lower compare year increase environmental provision corporate general administration change mchf mchf local currency administration restructuring expense general item general administration core basis global restructure legal environmental settlement total ifrs basis foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report local currency swiss franc change local currency change chf sale core operate profit exchange rate swiss franc december average december average usd eur jpy average rate euro dollar currency low swiss franc compare yen currency strengthen swiss franc sale development result growth percentage point low swiss franc term compare local currency basis core operating profit growth express swiss franc percentage point low local currency slightly high impact different currency structure operating cost sale sensitivity group sale core operating profit absolute term movement foreign currency swiss franc show table currency sensitivity impact rise average exchange sale core operate profit rate versus swiss franc mchf mchf dollar euro japanese yen currency nonoperate result nonoperate result core basis change mchf mchf chf operating profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest nonoperate result ifrs basis change mchf mchf chf operating profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche finance report roche group financial review result include month interest expense new debt issue finance genentech transaction compare month increase fullyear effect partly offset low interest expense repayment bond note million swiss franc record loss early redemption debt financing cost increase million swiss franc million swiss franc exceed financial income million swiss franc addition comparative period include noncore financing cost million swiss franc directly attributable genentech transaction group effective tax rate core basis decrease slightly compare net income increase drive strong operating performance spite significantly low tamiflu sale overall low noncore item global restructuring charge amortisation impairment intangible asset significant charge incur respect operational excellence initiative core basis net income decrease slightly core net income attributable roche shareholder higher compare improve operating performance elimination noncontrolle interest compensate high financing cost arise genentech transaction net financial result core basis million chf financing cost financial income net financial result financial income financial income million swiss franc decline compare interest income income debt security million swiss franc decrease interest rate reduce debt security holding net foreign exchange result loss million swiss franc compare gain million swiss franc decline mainly currency devaluation venezuela net income equity security million swiss franc compare million swiss franc expect return pension plan asset million swiss franc compare increase value pension plan asset order execute genentech transaction group liquidate certain debt security cash result noncore net loss million swiss franc include ifrs financial income analysis financial income give note consolidated financial statement financing cost finance cost million swiss franc increase million swiss franc compare increase mainly million swiss franc loss early redemption debt group redeem september billion dollar note march exercise option redemption billion dollar note march interest expense million swiss franc increase million swiss franc reflect month financing cost compare month debt issue connection genentech transaction partly offset low interest expense follow repayment early redemption bond note interest cost pension plan million swiss franc remain stable prevail financial condition quarter group issue bond note advance genentech transaction total billion swiss franc series debt offering noncore interest expense instrument bridge period issue completion genentech transaction march million swiss franc include ifrs financing cost analysis financing cost give note consolidated financial statement income taxis group effective tax rate core basis decrease slightly percentage point reduction mainly month additional interest cost debt raise finance genentech transaction loss early redemption bond tax deductible tax benefit million swiss franc record noncore item describe compare tax benefit million swiss franc primarily low global restructuring cost record impact income taxis equity compensation plan analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate core basis global restructure intangible asset group effective tax rate ifrs basis roche finance report roche group financial review net income earning share net income attributable roche shareholder billions chf core eps chf group net income increase billion swiss franc compare increase strong operating performance spite significantly low tamiflu sale overall low noncore item global restructuring charge amortisation impairment intangible asset exclude noncore item core net income decrease slightly portion attributable roche shareholder rise ifrs net income attributable roche shareholder rise billion swiss franc comparative period include million swiss franc attributable genentech noncontrolle interest march genentech transaction positive impact net income attributable roche shareholder earning share synergy saving elimination allocation noncontrolle interest compensate cost finance transaction dilute eps chf chf change ifrs basis core increase dilute eps increase net income attributable roche shareholder describe core eps exclude noncore item global restructuring charge amortisation impairment intangible asset increase swiss franc local currency supplementary net income ep information give page include calculation core ep reconcile group publish ifrs result cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow pharmaceutical diagnostic corporate group mchf mchf mchf mchf operating profit operate profit cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit operating profit cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit cash adjustment include elimination depreciation amortisation impairment charge property plant equipment intangible asset replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent detail breakdown provide free cash flow group billion swiss franc compare billion swiss franc decrease billion swiss franc drive high interest dividend payment nonrecurrence onetime tax benefit increase net working capital follow settlement unusually high accrual end operating profit increase operate free cash flow decrease billion swiss franc mainly cause increase net work capital billion swiss franc particular payment certain large yearend accrual notably tamiflu royalty employee retention severance scheme capital expenditure property plant equipment include investment new pharmaceutical research production facility switzerland germany united states operate profit cash adjustment decrease billion swiss franc billion swiss franc mainly large noncash item genentech integration quarter large interest payment new debt issue comparable payment quarter debt single annual interest payment quarter year main reason decrease free cash flow treasury activity billion swiss franc result overall outflow billion swiss franc total taxis pay billion swiss franc higher comparative period total tax payment unusually low onetime billion swiss franc tax benefit settlement stock option genentech employee closing genentech transaction march roche finance report roche group financial review total dividend pay billion swiss franc increase billion swiss franc compare reflect increase roche group dividend year net debt millions chf december cash cash equivalent marketable security longterm debt shortterm debt net debt begin period free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt december cash cash equivalent marketable security longterm debt shortterm debt net debt end period net debt position group billion swiss franc end decrease billion swiss franc december mainly free cash flow billion swiss franc describe outflow billion swiss franc come mainly transaction equity instrument execute cover exposure equity compensation plan issue employee addition billion swiss franc pay business combination mainly marcadia net debt position improve translation gain billion swiss franc consolidation total debt group affiliate strong swiss franc compare dollar improvement partially offset payment group billion swiss franc hedge collateral arrangement set follow financing genentech transaction group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar total exposure hedge issuance bond note approximately billion swiss franc note consolidated financial statement collateral agreement enter derivative counterpartie mitigate counterparty risk fair value derivative instrument go strengthen dollar euro cash collateral billion swiss franc deliver roche decrease december cash collateral balance favour roche billion swiss franc billion swiss franc december collateral balance relation hedge nonus dollardenominate bond note mainly sensitive foreign exchange rate dollar euro swiss franc pound sterling currently collateral balance move approximately million dollar foreign exchange rate simultaneously collateral volatility decrease million dollars movement foreign exchange rate mid nonus dollardenominated bond note repay realise loss derivative billion swiss franc relate mainly hedge nonus dollar denominate bond note redemption date billion dollar billion euro float rate note billion dollar genentech senior note early redemption note september principal value billion dollar march main factor decline billion swiss franc liquid fund impact net debt position balance sheet balance sheet billion chf capitalisation billion chf liability asset debt plus equity condense balance sheet december december mchf mchf change property plant equipment goodwill intangible asset noncurrent asset cash marketable security current asset total asset debt current noncurrent noncurrent liability current liability total liability total net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity debt equity capitalisation consolidated balance sheet give consolidated financial statement noncurrent asset property plant equipment decline particular impairment result operational excellence announcement site closure diagnostic austria switzerland euro dollar significantly weaken respectively swiss franc goodwill intangible asset decline drive amortisation impairment weak euro majority impairment intangible asset result portfolio prioritisation decision operational excellence initiative roche finance report roche group financial review current asset account receivable inventory increase moderately local currency weaken euro impact overall balance swiss franc carry value derivative asset decrease billion swiss franc consistent decrease carry value debt hedge cash marketable security decline describe cash flow net debt commentary debt carry value debt mainly finance genentech transaction decrease billion swiss franc reduction reflect redemption date billion dollar billion euro float rate note billion dollar genentech senior note early redemption september billion dollar note march detailed reconciliation debt movement provide note consolidated financial statement noncurrent current liability overall balance decrease billion swiss franc mainly repayment billion swiss franc collateral payable fair value derivative decline addition account payable accrue liability decrease billion swiss franc payment accrue royalty notably respect tamiflu sale second half accrue employee retentionseverance scheme total net assetsequity significant movement equity net income billion swiss franc dividend payment billion swiss franc overall capitalisation total debt plus equity decline debt significantly low repayment equity high net income offset dividend end equity capitalisation compare year previously debt finance genentech transaction group issue bond note equivalent billion swiss franc february march bond note raise early roughly repay december include early redemption note september principal value billion dollar march addition december group resolve exercise option redemption portion dollar fix rate note march total principal billion dollar billion dollar redeem march portion note show table maturity schedule group bond note outstanding december show table include instrument issue prior genentech transaction bond note nominal amount december contractual maturity dollar euro sterling swiss franc principal principal principal principal total total musd meur mgbp mchf musd mchf total total translate december exchange rate proceed bond note swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate ongoing business free cash flow billion swiss franc include cash generate operation payment interest tax dividend second half free cash flow inflow billion swiss franc half free cash flow outflow billion swiss franc include billion swiss franc payment annual dividend shortterm financing requirement group commercial paper programme united states issue billion dollar unsecured commercial paper note commit credit line billion euro million dollar available backstop line commercial paper note total billion dollar outstanding december longerterm financing group maintain strong longterm investmentgrade credit rating standard poor moodys facilitate efficient access international capital market describe commentary net debt position group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar time collateral agreement enter derivative counterpartie mitigate counterparty risk pension postemployment benefit postemployment benefit plan classify define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation minor relatively remote possibility arise fund asset management group define benefit plan oversee corporate level plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource roche finance report roche group financial review funding status define benefit pension postemployment benefit plan mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation funding status overall funding status group define benefit plan stable main movement come increase fair value plan asset recover offset increase define benefit obligation arise decrease discount rate group continues closely monitor fund status major pension fund addition cash injection group initiate plan change local pension plan example major pension fund remove early retirement incentive group continue introduce flexible retirement model anticipation age workforce expense record income statement total pension expense relate group define benefit plan million swiss franc compare million swiss franc decrease primarily higher expect return plan asset arise mainly consequence high asset base start addition curtailment gain million swiss franc compare million swiss franc base revise actuarial assumption end total pension expense expect broadly stable compare exclude curtailment effect detail group pension postemployment benefit give note consolidated financial statement roche security share price market capitalisation december change share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group healthcare company list term total shareholder return tsr share price growth plus dividend measure swiss franc actual exchange rate yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group actual exchange rate peer group abbott laboratories amgen astella astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline johnson johnson merck novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche peer set index propose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment share nonvoting equity security issue billion swiss franc billion swiss franc result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page finance report information share nonvoting equity security chf chf change basic eps dilute eps core eps equity attributable roche shareholder share dividend share detail refer note consolidated financial statement page finance report payout ratio calculate dividend share divide core earning share roche finance report roche group financial review financial risk december group net debt position billion swiss franc december billion swiss franc financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement roche reduce money market portfolio billion swiss franc instrument mature sell cash marketable security mchf total mchf total cash cash equivalent money market instrument bond debenture investment share total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group billion swiss franc fix income marketable security remain strong invest aaaa range note previously group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables billion swiss franc begin year increase financial difficulty certain southern european country particularly greece group lead supplier greek healthcare sector trade receivables greek public customer second half group accept offer greek government settle large part trade receivable zero coupon government bond redeemable government bond receive late december group expect receive remain government bond half group carefully monitor situation assess option manage counterparty exposure bad debt provision increase reflect development liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year despite total debt billion swiss franc december roche enjoy strong longterm investmentgrade credit rating standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total billion swiss franc december billion swiss franc billion swiss franc serve backstop line commercial paper programme december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price var datum table indicate economic loss level period month probability exceed actual future economic gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include credit risk component market risk financial instrument december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total december total var financial asset liabilitie million swiss franc december million swiss franc interest rate var decrease million swiss franc reflect age debt repayment debt high duration fix income asset hold issue debt hold amortise cost interest rate var sole metric economic fair value change impact carry value profit loss group foreign exchange var basically remain stable price risk arise mainly movement price equity security decline equity security holding reduce december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration information financial risk management financial risk var methodology include note consolidated financial statement international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group early adopt revise version ifrs business combination ias consolidated separate financial statement require implement january late group implement amendment exist standard interpretation material impact group overall result financial position roche finance report roche group roche group consolidate financial statement roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf disclose note income statement restate follow accounting policy change adopt reconciliation previously publish income statement provide note roche finance report roche group roche group consolidate financial statement roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset associate financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche finance report roche group roche group consolidate financial statement roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease work capital payment define benefit postemployment plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiarie interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement change ownership interest subsidiary genentech memory equity contribution noncontrolle interest interest pay dividend pay genentech equity compensation plan equitysettle equity compensation plan net transaction equity instrument chugai share repurchase finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december disclose note statement cash flow restate follow accounting policy change adopt change disposal product total million swiss franc report operate invest cash flow roche group consolidate statement change equity million chf reserve non share retain fair control total capital earning value hedging transl ation total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income business combination dividend pay equity compensation plan net transaction equity instrument chugai share repurchase change ownership interest subsidiary genentech memory change noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income dividend pay equity compensation plan net transaction equity instrument change noncontrolle interest equity contribution noncontrolle interest movement december roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director january subject approval annual general meeting shareholder march preparation consolidate financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change change accounting policy arise application new revise standard interpretation apply retrospectively specify transitional requirement particular standard interpretation retrospective application require result comparative period opening balance period restate new accounting policy apply case transitional requirement particular standard interpretation specify change apply prospectively prospective application require new accounting policy apply result current period comparative period restate addition comparative reclassify extend previously report result account presentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right currently exercisable potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control investment associate account equity method company group exercise power exercise significant influence control normally evidence group own voting right currently exercisable potential voting right company balance transaction associate result unrealised income eliminate extent group interest associate interest joint venture report linebyline proportionate consolidation method segment report determination group operate segment base organisation unit information report group management group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party certain headquarter activity report corporate consist corporate headquarters include corporate executive committee corporate communication corporate human resource corporate finance include treasury taxis pension fund management corporate legal corporate safety environmental service subdivisional information roche pharmaceutical chugai previously aggregate operating segment pharmaceutical division present transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer equity consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity disposal foreign entity identify cumulative currency translation difference equity relate foreign entity recognise income gain loss divestment roche finance report roche group note roche group consolidate financial statement revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid united states similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profit sharing arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research cost cost incur purpose gain new scientific technical knowledge understanding cost expense incur internal development cost cost incur application research finding knowledge plan develop new product commercial production cost qualify capitalisation intangible asset follow criterion demonstrate technical feasibility complete development project successfully available use sale intention complete development project ability use sell result development project development project generate economic benefit normally evidence existence size market result project product result project availability adequate technical financial resource complete development project ability measure development expenditure reliably qualify capitalisation intangible asset development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation meet prior obtain marketing approval regulatory authority major market internal development cost meet criterion expense incur postmarkete study regulatory approval phase cost pharmaceutical business expense incur generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason safety surveillance design detect rare long term adverse effect large patient population long time period possible early stage development cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure addition internal research development activity group party inlicense similar arrangement alliance partner group acquire inprocess research development asset business combination purchase specific asset inprocess research development resource acquire inlicense arrangement business combination separate purchase capitalise intangible asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy review impairment set impairment property plant equipment intangible asset policy available use intangible asset amortise straightline basis period expect benefit review impairment reporting date research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset license milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive party upfront milestone similar payment relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned liability longterm employee benefit discount account time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company group contribution define contribution plan charge appropriate income statement head operating result year relate accounting reporting define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth long term expect rate return plan asset discount rate base market yield highquality corporate bond country concern past service cost allocate average period benefit vested current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss consist difference assumption actual experience effect change actuarial assumption record directly equity pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative roche finance report roche group note roche group consolidate financial statement unrecognise past service cost adjustment arise limit recognition asset define benefit plan record directly equity equity compensation plan certain employee group participate equity compensation plan include separate plan genentech prior genentech transaction chugai fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity cashsettle plan liability record measure fair value report date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt asset acquire finance lease depreciate accordance group policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease group lessor primarily occur diagnostic division asset subject finance lease initially report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease subsequently recognise earn income term lease base effective interest rate method lease income operating lease recognise lease term straightline basis business combination goodwill business combination account acquisition method accounting consideration transfer business combination measure fair value date acquisition consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group fair value consideration transfer include contingent consideration arrangement fair value directly attributable acquisitionrelated cost expense current period report general administration expense date acquisition group recognise identifiable asset acquire liability assume non control interest acquire business identifiable asset acquire liability assume initially recognise fair value group acquire ownership acquire business noncontrolle interest record proportion fair value acquire net asset attributable noncontrolle interest goodwill record surplus consideration transfer group interest fair value acquire net asset goodwill fair value adjustment record asset liability acquire business functional currency business initial accounting business combination incomplete end reporting period provisional amount measurement period provisional amount retrospectively adjust additional asset liability recognise reflect new information obtain fact circumstance exist acquisition date affect measurement amount recognise date know measurement period exceed month date acquisition goodwill amortise assess possible impairment reporting date additionally test annually impairment goodwill arise investment associate surplus cost investment group share fair value net identifiable asset goodwill record investment associate change ownership interest subsidiary account equity transaction occur control obtain result loss control intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination fair value allocate acquisition account intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy impairment goodwill goodwill assess possible impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit describe note recoverable cashgenerate unit high fair value cost sell value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss methodology impairment testing describe note roche finance report roche group note roche group consolidate financial statement inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record difference carry value recoverable objective evidence group able collect amount trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience longterm account receivable discount account time value money material cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition statement cash flow provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available fair value hierarchy valuation technique incorporate observable market datum market condition factor likely affect fair value financial instrument valuation technique typically derivative financial instrument fair value financial asset liability report date materially different report carry value specifically mention note consolidated financial statement information fair value hierarchy include note risk management financial asset financial asset principally investment include marketable security classify fairvalue throughprofitorloss availableforsale heldtomaturity loan receivables fairvaluethrough profitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethroughprofitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset security fix maturity group intent ability hold maturity loan receivables financial asset create group acquire issuer primary market nonderivative financial asset fix determinable payment quote active market financial asset consider availableforsale financial asset initially record fair value include transaction cost asset fair valuethroughprofitorloss exclude transaction cost purchase sale recognise settlement date fairvaluethroughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldto maturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record equity interest calculate effective interest rate method foreign exchange component availableforsale financial asset sell impair dispose cumulative gain loss previously recognise equity include financial income current period loan receivables subsequently carry amortise cost effective interest rate method financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity security market value original cost net previous impairment consider impair availableforsale equity security market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment sustained sixmonth period consider objective evidence impairment movement fair value record equity objective evidence impairment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry equity difference original cost net previous impairment fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly equity financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer interest transfer financial asset create retain group recognise separate asset liability derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedging instrument discuss hedge policy change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract carry amortise cost hedge accounting purpose hedge accounting hedging relationship type fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation roche finance report roche group note roche group consolidated financial statement qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence cash flow hedge hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion report financial income hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial asset liability cumulative change fair value hedge instrument record equity include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrument record equity reclassify income debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method group derecognise financial liability contractual obligation discharge cancel expire certain debt instrument designate fairvaluethroughprofitorloss result relevant information eliminate significantly reduce measurement recognition inconsistency debt instrument report fair value base quote price active market movement fair value report financial income group instrument redeem july disclose note taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future deferred income tax asset liability recognise temporary difference tax basis asset liability carry value financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate discontinue business noncurrent asset hold sale discontinue business component group business represent separate major line business geographical area operation subsidiary acquire exclusively view resale reclassification discontinue business occur disposal operation meet criterion classify hold sale early disposal group group assets dispose group single transaction liability directly associate asset transfer transaction asset liability disposal group reclassify held sale value recover principally sale continue use disposal group available sale current condition sale highly probable immediately classification hold sale measurement asset liability disposal group update accordance applicable accounting policy initial classification hold sale disposal group recognise low carrying value fair value cost sell impairment loss initial classification hold sale include income statement equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet potential obligation employee arise respect certain group equity compensation plan management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise consolidated financial statement management judgement particularly require assess substance transaction complicate structure legal form include limited follow area revenue recognition nature group business sale transaction simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement roche finance report roche group note roche group consolidate financial statement consolidation subsidiary associate group periodically undertake transaction involve obtain right control significantly influence operation company transaction include acquisition equity company purchase certain asset assumption certain liability contingent liability company enter alliance agreement company include transaction involve special purpose entity similar vehicle case management make assessment group right control significantly influence company operation base assessment company consolidated subsidiary associate company make assessment management consider underlie economic substance transaction contractual term business combination group acquire control business consideration transfer allocate identifiable asset acquire liability assume non control interest acquire business residual record goodwill process involve management make assessment fair value item management judgement particularly involve recognition measurement follow item intellectual property include patent licence trademark similar right currently market product right scientific knowledge associate project currently research development phase contingency legal environmental matter contingent consideration arrangement recoverability accumulate tax loss previously incur acquire company case management make assessment base underlying economic substance item concern contractual term order fairly present item lease group party leasing arrangement lessee lessor treatment leasing transaction financial statement mainly determine lease consider operate lease finance lease make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment key assumption source estimation uncertainty preparation consolidate financial statement conformity ifrs require management estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base historical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base result new information experience change recognise period estimate revise key assumption future key source estimation uncertainty significant risk cause material adjustment carry value asset liability month describe revenue recognition circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary sale allowance group provision accrual expect sale return chargeback rebate include medicaid united states similar rebate country december total million swiss franc estimate base analyse exist contractual legislativelymandate obligation historical trend group experience management believe total provision accrual item adequate base currently available information deduction base management estimate subject change well information available change arise impact provision accrual recognise balance sheet future period consequently level sale recognise income statement future period property plant equipment intangible asset include goodwill group property plant equipment carry value million swiss franc disclose note goodwill carry value million swiss franc note intangible asset carry value million swiss franc note asset review annually impairment describe assess impairment exist estimate future cash flow expect result use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment change discount rate lead impairment pension postemployment benefit group employee participate post employment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result change market economic condition high low withdrawal rate long short life span participant change factor assess difference impact asset liability recognise balance sheet future period legal provision group company party legal proceeding include claim arise trade significant matter describe note legal provision december total million swiss franc management believe total provision legal proceeding adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue additional claim cover exist provision insurance assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact provision recognise balance sheet future period roche finance report roche group note roche group consolidate financial statement environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site include landfill treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site method extent remediation percentage problematic material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue effect resolution environmental matter result operation predict uncertainty concern time future expenditure change arise impact provision recognise balance sheet future period income taxis december net liability current income taxis million swiss franc net asset defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis estimate base interpretation exist tax law regulation management believe estimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level research development spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period change accounting policy group early adopt revise version ifrs business combination ias consolidated separate financial statement require implement january late group implement amendment exist standard interpretation material impact group overall result financial position presentation income statement group certain presentational change income statement light current international industry practice take account late regulatory guidance change apply retrospectively list term exceptional item long financial statement income statement heading major legal case change group organisation long show separately face income statement income expense include general administration disclosure note respectively subtotal operating profit exceptional item delete redundant income statement head exceptional financing cost long show separately face income statement income expense include financial income financing cost appropriate disclosure note income statement head income taxis exceptional item long show separately face income statement income expense include income taxis disclosure note income statement year end december restate follow change set table restate consolidated income statement year end december million chf originally publish reclassification restate sale royalty operating income cost sale marketing distribution research development general administration major legal case change group organisation operate profit associate financial income financing cost exceptional financing cost profit taxis income taxis income taxis exceptional item net income improvement ifrs ias statement cash flow group minor presentational change statement cash flow follow implementation improvement ifrs issue april change disposal product total million swiss franc report operate invest cash flow statement cash flow year end december restate accordingly group currently assess potential impact new revise standard interpretation effective january group early adopt group anticipate material impact group overall result financial position roche finance report roche group note roche group consolidate financial statement operating segment information divisional information millions chf pharmaceutical diagnostic corporate group revenue external ustomer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expenses pharmaceutical subdivisional information millions chf roche pharmaceutical pharmaceutical chugai division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result subdivisional profit elimination interdivisional profit operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group roche finance report roche group note roche group consolidate financial statement information geographical area millions chf revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give page respectively sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue european union information base members december major customer national wholesale distributor amerisourcebergen corp represent approximately billion swiss franc billion swiss franc group revenue approximately revenue pharmaceuticals operating segment residual diagnostic segment group report substantial revenue national wholesale distributor cardinal health inc mckesson corp total customer represent approximately quarter group revenue genentech effective september roche group acquire majority interest approximately genentech inc biotechnology company united states common stock genentech publicly trade list new york stock exchange symbol dna december group interest genentech genentech transaction march roche enter merger agreement genentech pursuant group successful tender offer purchase share genentech own group usd share cash genentech transaction result genentech wholly own subsidiary group effective march cash consideration purchase public share include share issuable genentech outstanding employee stock option plan payment relate fee expense amount approximately billion dollar set table amount record equity change ownership interest subsidiary genentech transaction usd million chf million purchase publicly hold share settlement outstanding employee stock option directly attributable transaction cost total cash consideration income tax effect change ownership interest subsidiary translate spot rate date transaction march usd chf group finance genentech transaction combination group fund bond note commercial paper group raise net proceed approximately billion swiss franc series debt offering describe note newly issue debt senior unsecured guarantee roche holding ltd impact genentech transaction relate reorganisation roche pharmaceutical business group result describe note roche finance report roche group note roche group consolidate financial statement chugai effective october roche group chugai complete alliance create lead research drive japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone result jgaap basis result chugai consolidated roche group accordance ifrs roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement sign roche right refusal development marketing chugais development compound market outside japan exclude south korea chugai decide require partner activity agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment armslength basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement armslength basis research collaboration agreement roche chugai enter research collaboration agreement area smallmolecule synthetic drug research biotechnologybase drug discovery dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item chugai share repurchase chugai repurchase common share result group ownership chugai increase total cash outflow include repurchase fractional share billion japanese yen million swiss franc share repurchase matter detail chugais equity compensation plan give note financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity security derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security gain loss liquidation debt security gain loss debt security derivative net writedown impairment longterm loan net interest income income debt security expect return plan asset define benefit plan foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income roche finance report roche group note roche group consolidate financial statement financing cost million chf year end december interest expense interest expense incur newly issue bond note bridge period amortisation debt discount gain loss debt derivative net gain loss redemption repurchase bond note net gain loss financial liability fairvaluethroughprofitorloss net time cost provision interest cost define benefit plan total financing cost net financial income million chf year end december financial income financing cost net financial income financial result treasury management financial result pension management net financial income genentech transaction financing cost describe note effective march group purchase publicly own share genentech usd share cash total cash consideration transaction include share issuable genentech outstanding employee stock option plan payment relate fee expense approximately billion swiss franc order execute transaction group liquidate certain debt security cash result net loss transaction million swiss franc furthermore prevail financial condition group issue bond note advance transaction total billion swiss franc series debt offering describe note interest expense instrument bridge period issue completion genentech transaction march million swiss franc previously present exceptional financial cost disclose note income expense long show separately face income statement include financial income financing cost appropriate appropriate reclassification disclosure note income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total income expense disclose note income statement head income taxis exceptional item long show separately face income statement income expense include income taxis appropriate reclassification disclosure note include restatement reconciliation group effective tax rate table group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate average expect rate increase compare significant local tax rate change main operating area group compare main driver increase come relatively high local tax rate average group rate group taxable profit increase significantly result increase percentage contribute overall mix group profit increase profit mainly low global restructuring cost record billion dollar compare billion dollar offset increase interest expense group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect utilisation previously unrecognise tax loss nontaxable incomenondeductible expense equity compensation plan research development manufacturing tax credit state tax impact difference group effective tax rate impact equity compensation plan effective tax rate increase benefit mainly onetime impact accelerate vest genentech plan increase profit contribution result high state taxis increase group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity million swiss franc million swiss franc exclude accelerate vest impact genentech plan income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately million swiss franc million swiss franc record roche finance report roche group note roche group consolidate financial statement tax effect comprehensive income millions chf pretax tax aftertax pretax tax aftertax benefit benefit availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer income taxis asset liability net defer income tax asset liability movement amount record balance sheet current income taxis show table current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay charge credit income statement current income taxis adjustment recognise current tax prior period charge credit equity equity compensation plan transaction shareholder currency translation effect net current income tax asset liability december defer income tax asset recognise tax loss carryforward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable mchf tax rate mchf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc movement amount record balance sheet defer income taxis show table defer income taxis movement recognise net asset liability millions chf property plant equipment temporary intangible asset difference total year end december net defer income tax asset liability january lonza singapore acquisition business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december year end december net defer income tax asset liability january marcadia acquisition business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december business combination acquisition marcadia effective december group acquire control interest marcadia biotech inc marcadia privately own company base carmel indiana marcadia biopharmaceutical company focus develop broad portfolio drug candidate treatment diabete obesity marcadia report roche pharmaceutical operating segment acquisition marcadia allow group integrate marcadias development pipeline research development portfolio marcadia research programme focus new peptide therapie treatment type diabetes obesity include generation peptide mar novel compound currently phase development base marcadias unique peptide chemistry technology peptide design offer patient improve efficacy safety convenience roche finance report roche group note roche group consolidate financial statement total purchase consideration million swiss franc million swiss franc pay cash million swiss franc arise contingent consideration arrangement payment arrangement base achievement separate performance milestone arise range outcome undiscounte zero million dollar equivalent million swiss franc december exchange rate liability million swiss franc recognise acquisition date base management well estimate probability adjust expect cash outflow arrangement december recognise arrangement unchanged base recent management estimate purchase consideration allocate show table asset liability amount allocate provisional base preliminary information valuation asset liability marcadia subject adjustment new information obtain fact circumstance exist acquisition date marcadia acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use inventory defer income taxis cash net asset liability net identifiable asset goodwill purchase consideration goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc acquisition effective group acquire control interest medingo ltd medingo majorityowned subsidiary elron group base israel medingo engage development semidisposable insulin patch pump report diagnostic operating segment acquisition broaden group portfolio innovative insulin delivery technology strengthen position diabete care business total purchase consideration million swiss franc million swiss franc pay cash million swiss franc arise contingent consideration arrangement payment arrangement base achievement separate performance milestone arise range outcome undiscounte zero million dollar equivalent million swiss franc december exchange rate liability million swiss franc recognise acquisition date base management good estimate probabilityadjuste expect cash outflow arrangement december recognise arrangement unchanged base recent management estimate effective september group acquire control interest bioimagene inc bioimagene privately own company base sunnyvale california bioimagene engage digital pathology workflow analysis field report diagnostic operating segment acquisition complement strengthen group portfolio image analysis diagnosis total purchase consideration million swiss franc cash minor business combination diagnostic business total purchase consideration million swiss franc cash combine purchase consideration allocate follow acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use technology intangible use inventory defer income taxis cash net asset liability net identifiable asset liability goodwill purchase consideration goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivable directly attributable transaction cost million swiss franc incur acquisition report general administration expense current period operating result roche pharmaceutical diagnostic operating segment million swiss franc roche finance report roche group note roche group consolidate financial statement acquisition impact result million chf revenue inventory amortisation external fair value intangible operating customer adjustment asset profit net income impact report result marcadia pharmaceutical division medingo bioimagene minor business combination diagnostic division group estimate impact result acquisition assume effective january marcadia pharmaceuticals division medingo bioimagene minor business combination diagnostic division group figure exclude directly attributable acquisitionrelated cost million swiss franc relate acquisition pharmaceutical division million swiss franc relate acquisition diagnostic division correspond tax impact exclude figure exclude integration cost million swiss franc relate medingo bioimagene correspond tax impact exclude acquisition net cash outflow millions chf cash consideration cash net cash pay acquire company outflow marcadia acquisition total acquisition lonza singapore genentech enter supply agreement manufacture certain genentech product facility construction singapore lonza group ltd lonza genentech commit fund precommissione production qualification cost facility fda licensure genentech commit purchase product successfully manufacture facility period year commission facility genentech receive exclusive option purchase lonzas singapore facility period year fda licensure purchase price million dollar genentech enter loan agreement lonza advance million dollar lonza construction singapore facility genentech exercise option purchase facility outstanding advance offset purchase price genentech exercise purchase option advance offset supply purchase regardless purchase option exercise genentech oblige milestone payment million dollar certain performance milestone meet facility construct accounting purpose nature supply agreement genentech involvement construction building genentech consider owner asset construction period fund construct building shell infrastructure cost pay lonza december construction progress total million swiss franc capitalise liability financing obligation total million swiss franc record net million dollar million swiss franc advanced genentech lonza august genentech singapore pte ltd genentech singapore exercise option purchase ownership lonza biologic singapore pte ltd lonza singapore lonza singapore cell culture biologic manufacturing facility mechanically complete expect produce avastin bevacizumab bulk drug substance litre fermentation capacity locate approximately acre option additional acre integration roche genentechs combine technical operation biotechnology production facility singapore merge operate roche singapore technical operation exercise option resultant merger approximately lonza employee join genentech singapore technical operation total site headcount approximately august previous accounting treatment describe construction progress total million dollar million swiss franc capitalise similar liability financing obligation record addition million dollar advanced genentech lonza transaction value million dollar consist million dollars singapore facility million dollar milestone payment million dollar offset loan previously genentech lonza net transaction value million dollar million swiss franc million dollar million swiss franc cash payment million dollar million swiss franc accrue milestone payment accounting purpose million dollar million swiss franc allocate settlement exist financing obligation million dollar million swiss franc acquisition lonza singapore business allocate follow lonza singapore acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset inventory defer income taxis cash net asset liability net identifiable asset goodwill purchase consideration acquisition effective january group acquire control interest memory pharmaceuticals corp memory publicly own company base montvale new jersey list nasdaq symbol memy memory develop innovative drug candidate treatment debilitate central nervous system cns disorder alzheimer disease schizophrenia memory report roche pharmaceutical operating segment acquisition strengthen group research development pipeline area alzheimer disease purchase consideration million swiss franc pay cash roche finance report roche group note roche group consolidate financial statement minor business combination diagnostic business total purchase consideration million swiss franc million swiss franc cash million swiss franc contingent consideration arrangement liability million swiss franc recognise acquisition date base management well estimate time probabilityadjuste expect cash outflow arrangement december recognise arrangement reduce zero base recent management estimate time combine purchase consideration allocate follow acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment goodwill intangible asset product intangible use marketing intangible product intangible available use inventory provision defer income taxis cash net asset liability net identifiable asset liability noncontrolle interest goodwill purchase consideration subsequent effective date acquisition january group purchase remain share memory hold party group interest memory cash consideration million swiss franc record equity change ownership interest subsidiary goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc include allowance doubtful account million swiss franc directly attributable acquisitionrelated cost million swiss franc incur acquisition report general administration expense current period operating result pharmaceutical operating segment million swiss franc diagnostic operating segment million swiss franc acquisition net cash outflow millions chf cash consideration cash net cash pay acquire company outflow lonza singapore acquisitions total cash consideration include subsequent payment million swiss franc purchase remain share memory hold party group interest memory report finance cash flow statement cash flow head change ownership interest subsidiary contingent consideration arrangement group party certain contingent consideration arrangement arise previous business combination arrangement provision arrangement record provision note set table provision contingent consideration arrangement millions chf january additional provision create unused amount reverse utilise year unwind discount business combination marcadia medingo minor business combination currency translation effect december expect outflow resource year year year year total global restructuring plan genentech transaction restructure integration july group announce offer purchase outstanding share genentech follow closing transaction genentech south san francisco site headquarters group combine pharmaceutical operation united states july group announce roche pharmaceutical business close manufacturing operation site nutley new jersey commercial operation move genentech research site palo alto california closed research activity transfer nutley genentech subsequent announcement initial restructuring activity start nutley palo alto site roche finance report roche group note roche group consolidated financial statement describe note genentech transaction complete effective march follow pharmaceutical division initiate detailed integration programme align genentech business rest roche pharmaceutical business genentechs south san francisco site establish headquarters pharmaceutical business include commercial operation market genentech research early development set autonomous unit genentech latestage development activity integrate global pharmaceutical division network integration programme include prioritise project shared portfolio eliminate activity duplicate long require notably administration function follow completion transaction pharmaceutical division carry detailed reassessment global manufacturing network particular emphasis biotech manufacturing facility result manufacturing facility construction project discontinue notably bulk drug production unit site vacaville california impairment charge million swiss franc record respect facility previous carrying value billion swiss franc asset carry value billion swiss franc subsequently transfer facility continue use restructuring activity substantially complete end total cost billion swiss franc include billion swiss franc incur total billion swiss franc approximately billion swiss franc noncash genentech transaction restructure integration cost millions chf employeerelate cost termination cost pension postemployment benefit genentech stock option accelerate vest expense retention plan employee benefit employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment site closure cost total site closure cost impairment intangible asset reorganisation expense total operational excellence november group announce detail concern operational excellence global restructuring plan plan aim adapt cost structure increasingly challenge market environment achieve significant efficiency productivity gain plan measure enable sustained investment research product development strengthen group longterm innovation capability implementation plan include reduce work force position worldwide group current work force year plan job reduction occur pharmaceutical division particularly division global sale marketing organisation manufacture approximately job transfer roche site position outsource party combination plan job reduction transfer affect position overall plan group intends seek buyer pharmaceutical division manufacturing site florence south carolina boulder colorado united states research development site kulmbach germany madison wisconsin united states plan preliminary stage site operation follow comprehensive portfolio review pharmaceutical division decide discontinue certain activity research early development addition certain product development activity discontinue transfer roche site party result decision intangible asset carry value million swiss franc fully write diagnostic division site graz austria burgdorf switzerland closed impairment charge million swiss franc record respect facility previous carrying value million swiss franc group currently anticipate restructure activity substantially complete end total cost expect order billion swiss franc include billion swiss franc incur operational excellence restructuring cost millions chf employeerelate cost termination cost pension postemployment benefit equity compensation plan accelerate vest expense employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment environmental remediation cost site closure cost total site closure cost impairment intangible asset reorganisation expense total roche finance report roche group note roche group consolidate financial statement classification operational excellence restructuring cost millions chf depreciation amortisation impairment cost total cost sale roche pharmaceutical diagnostic marketing distribution roche pharmaceutical diagnostic research development roche pharmaceutical diagnostic general administration roche pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total employee benefit employee remuneration million chf wage salary social security cost define contribution postemployment plan operating expense define benefit postemployment plan equity compensation plan termination cost genentech transaction restructuring integration operational excellence employee benefit employee remuneration include operating result expect return plan asset define benefit postemployment plan interest cost define benefit postemployment plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit employee benefit include million swiss franc expense relate genentech employee retention program charge employee benefit operating result include relevant expenditure line function expect return plan asset interest cost define benefit plan include financial income financing cost respectively note pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise consequently group postemployment benefit plan classify define benefit plan purpose financial statement define contribution plan define contribution plan typically consist payment employee group fund administer party payment group million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution define benefit plan group major define benefit plan locate switzerland united states germany united kingdom japan plan usually establish trust independent group fund payment group employee case notably major define benefit plan germany plan unfunded group pay pension retire employee directly financial resource current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss record directly equity recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity roche finance report roche group note roche group consolidate financial statement define benefit plan expense millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total current service cost past service cost gain loss curtailment gain loss settlement total operating expense expect return plan asset interest cost total financial income expense total expense recognise income statement funding group define benefit plan oversee corporate level qualified independent actuary carry valuation regular basis major plan annually report date fund plan usually trust independent group finance net assetliability recognise group balance sheet correspond overunder funding plan adjust unrecognised past service cost unfunded plan group meet pension obligation directly financial resource liability define benefit obligation record group balance sheet pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan amount recognise balance sheet postemployment benefit predominantly noncurrent report noncurrent asset liability define benefit plan fund status millions chf fund unfunded fund unfunded plan plan total plan plan total fair value plan asset define benefit obligation funding unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability report define benefit plan reimbursement right postemployment benefit asset postemployment benefit liability net recognise asset liability detailed information plan asset define benefit obligation give define benefit plan fair value plan asset reimbursement right millions chf fair value reim fair value reim plan bursement plan bursement asset right total asset right total january expect return plan asset actuarial gain loss currency translation effect employer contribution employee contribution benefit pay fund plan past service cost divestment subsidiary curtailment settlement december invest share equity instrument bond debenture debt instrument property asset total include fair value plan asset group share thousand share fair value million swiss franc thousand group nonvoting equity security fair value million swiss franc thousand nonvoting equity security total fair value million swiss franc roche finance report roche group note roche group consolidate financial statement define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost employee contribution actuarial gain loss currency translation effect benefit pay fund plan benefit pay unfunded plan past service cost divestment subsidiary curtailment settlement december fund plan unfunded plan actuarial assumption actuarial assumption unbiase mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter salary benefit level interest rate return investment cost medical benefit group operate define benefit plan country actuarial assumption vary base local economic social condition demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity mortality table major scheme germany heubeck table japan national census life table switzerland bvg united kingdom nonpensioner snal table rate year male year female future improvement medium cohort underpin united kingdom pensioner snal table rate year future improvement medium cohort underpin united states project rate employee turnover disability early retirement base historical behaviour group company financial assumption base market expectation period obligation settle range assumption actuarial valuation significant plan country stable currency interest rate show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate return plan asset expect rate salary increase immediate medical cost trend rate ultimate medical cost trend rate discount rate calculate discount present value define benefit obligation determine reference market yield highquality corporate bond government bond countrie deep market corporate bond currency term bond consistent obligation discount interest cost include income statement calculate multiply discount rate define benefit obligation expect return plan asset base market expectation expect return asset fund plan duration relate obligation take account split plan asset equity bond property investment calculation include assumption concern expect dividend interest income realise unrealised gain plan asset taxis administration cost bear plan base longterm market expectation actual performance continually monitor corporate management longterm nature obligation assumption matter return investment necessarily consistent recent historical pattern expect return plan asset include income statement calculate multiplying expect rate return fair value plan asset difference expect return actual return twelvemonth period actuarial gainloss record directly equity actual return plan asset gain million swiss franc gain million swiss franc expect rate salary increase calculate define benefit obligation current service cost include income statement base late expectation historical behaviour group company medical cost trend rate calculate define benefit obligation current service cost include income statement postemployment medical plan account benefit set plan term expect future change medical cost group major post employment medical plan employee rate drive development united states effect percentage point increase decrease medical cost trend rate show define benefit plan sensitivity medical cost trend rate millions chf current service cost interest cost define benefit obligation funding summary fiveyear summary funding status group define benefit plan show table roche finance report roche group note roche group consolidate financial statement define benefit plan summary funding status millions chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation increase decrease funding status arise experience adjustment fair value plan asset define benefit obligation increase decrease funding status arise change actuarial assumption fair value plan asset define benefit obligation cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution benefit pay unfunded plan estimate approximately million swiss franc amount record equity actuarial gain loss recognise statement comprehensive income loss million swiss franc loss million swiss franc pretax total december accumulate loss million swiss franc accumulate loss million swiss franc addition recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit asset recognition record directly equity adjustment decrease million swiss franc decrease million swiss franc employee stock option equity compensation plan group operate equity compensation plan include separate plan genentech prior genentech transaction chugai effective january group adopt ifrs sharebased payment matter standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement head general administration cost include million swiss franc expense accelerate vest genentech equity compensation plan follow genentech transaction note expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan special stock award roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche restrict stock unit plan chugai retirement stock acquisition right roche performance share plan roche stock appreciation right total equity compensation plan total operating expense equitysettle cashsettle roche finance report roche group note roche group consolidate financial statement cash inflow outflow equity compensation plan millions chf genentech equity compensation plan genentech stock option plan genentech employee stock purchase program total cash inflow genentech equity compensation plan equitysettle equity compensation plan roche option plan exercise chugai stock acquisition right exercise roche connect cost total equitysettle equity compensation plan cash outflow transaction equity instrument total cash inflow outflow equitysettle equity compensation plan net transaction equity instrument cashsettle plan include movement net work capital roche stock appreciation right net cash outflow transaction equity instrument arise sale purchase non vote equity security genussscheine derivative instrument thereon hold group potential conversion obligation arise group equitysettle equity compensation plan derivative instrument mainly consist option exercisable time maturity note addition cash flow completion genentech transaction remain outstanding genentech employee stock option fully redeem cash result cash outflow million swiss franc report change ownership interest subsidiary note roche longterm group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan follow integration genentech group establish restrict stock unit rsu plan award plan september employee genentech ssar issue accordance roche ssar plan regulation january include amendment effective january addenda include roche ssar plan addendum united states september remuneration committee determine number nonvoting equity security genussscheine available plan year regulation collectively provide million nonvoting equity security genussscheine available issuance roche ssar plan tenyear period rsus issue accordance roche restrict stock unit plan regulation effective september million nonvoting equity security genussscheine available issuance tenyear period detail plan give relevant section share option plan roche option plan award plan employee right purchase nonvoting equity security genussscheine exercise price specify grant date option non tradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche option plan movement number option outstanding number weight average number weight average option exercise price option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total genentech stock option plan genentech stock option plan adopt amend april genentechs shareholder approve equity incentive plan plan allow grant stock option incentive stock option stock purchase right employee director consultant genentech option grant nontradable equitysettle award tenyear duration vest phase basis year subject continued employment completion genentech transaction note remain outstanding option fully redeem cash accounting purpose remain fair value million swiss franc expense option fully vested time roche finance report roche group note roche group consolidate financial statement genentech stock option plan movement number option outstanding number weight average number weight average option exercise price option exercise price million usd million usd outstanding january grant forfeit exercise expired genentech transaction outstanding december exercisable chugai stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right entitle holder purchase chugai share specify exercise price right nontradable equitysettle award tenyear duration vest year chugai stock acquisition right movement number right outstanding weighted average weight average number exercise price number exercise price right jpy right jpy outstanding january grant forfeit exercise expired outstanding december exercisable chugai stock acquisition right term right outstanding december right outstanding right exercisable weighted average weighted average weight average number year remain exercise price number exercise price year grant outstanding contractual life jpy exercisable jpy award total issue share option issue share option include methodology calculate fair value main input valuation model describe issue share option plan roche chugai stock option plan acquisition right number option grant underlying equity roche nonvoting chugai share equity security block currency swiss franc japanese yen vest period progressively year year contractual life year year weight average fair value option issue option pricing model binomial binomial input option pricing model share price grant date exercise price expect volatility expect dividend yield early exercise factor expect exit rate volatility roche chugai option determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour equity compensation plan special stock awards march december group issue special stock award certain director management employee select discretion group award consist immediately vest nonvoting equity security genussscheine fair value award calculate basis market value roche nonvoting equity security date issue roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security genussscheine administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million programme operational october year cost plan million swiss franc million swiss franc report relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allow employee purchase genentech common stock low market value grant date purchase date total million share genentech common stock purchase result cash inflow million swiss franc cost plan million swiss franc report relevant expenditure line function completion genentech transaction note remain outstanding award fully redeem cash accounting purpose remain fair value million swiss franc expense award fully vested time roche finance report roche group note roche group consolidate financial statement roche stocksettle stock appreciation right introduction roche longterm group offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive non vote equity security genussscheine reflect value appreciation market price nonvoting equity security grant date exercise date right nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note roche ssar movement number right outstanding number weight average number weight average right exercise price right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total weight average fair value right grant calculate binomial model input model consistent roche option plan award give previously early exercise factor expect exit rate result weight average fair value right chf give total fair value million swiss franc charge vest period year roche restrict stock unit plan time september group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity security genussscheine vest threeyear period weight average fair value award grant chf calculate basis market value roche nonvoting equity security date issue discount account award accrue dividend vest period roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december exercisable chugai retirement stock acquisition right time chugai issue stock acquisition right lieu retirement gratuity system director abolish right issue thirtyyear duration vest holder retirement director chugai right entitle holder purchase chugai share exercise price japanese yen total fair value right issue equivalent million swiss franc million swiss franc calculate binomial model input consistent chugai stock appreciation right give previously roche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager programme establish beginning currently operate annual threeyear cycle term currently outstanding award set table nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director nontradable equitysettle awards award result zero nonvoting equity security depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million weight average fair value award grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history riskfree rate valuation take account define rank performance structure determine payout plan roche finance report roche group note roche group consolidate financial statement roche stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar non tradable cashsettle award exercise vest period year cash payment base market price group american depositary receipt adr point exercise exceed strike price grant price issuance follow implementation roche longterm group plan award cashsettle sar award roche stock appreciation right millions chf liability december intrinsic value vest right december roche stock appreciation right term right outstanding december right outstanding exercisable number outstanding exercisable weighted average year grant thousand expiry price usd feb total fair value december calculate binomial model input model adr price december usd exercise price give table input consistent roche option plan award give previously property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal lonza singapore acquisition business combination transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal marcadia acquisition business combination transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence result shorten useful life impairment impairment charge million swiss franc million swiss franc report cost sale million swiss franc million swiss franc research development million swiss franc million swiss franc report general administration major impairment report general administration relate discontinuation bulk drug production unit site vacaville california note roche finance report roche group note roche group consolidate financial statement borrowing cost total million swiss franc rate million swiss franc rate capitalise property plant equipment leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value future payment minimum lease payment year year year total future finance charge total future minimum lease ayments undiscounte addition genentech leasing arrangement disclose operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease payment noncancellable lease millions chf gross investment lease present value future minimum lease payment year year year total unearned finance income unguaranteed residual value net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income genentech leasing arrangement december genentech enter master lease agreement slough ssf llc subsequently acquire health care property hcp development property adjacent genentechs south san francisco site development include total building subject separate agreement contemplate master lease agreement hcp developer construct building shell building genentech finish interior build laboratory office space applicable construction building complete point lease term building deem begin construction final building complete lease term expire year occupation final building genentech fiveyear renewal option building option purchase building different date genentech right refusal respect build entire development hcp consider sell development december total carrying value property plant equipment agreement million swiss franc million swiss franc carry value genentech leasing obligation million swiss franc million swiss franc estimate total future minimum lease payment anticipate entire master lease agreement show estimate total future minimum lease payment hcp lease millions chf total minimum principal ground lease interest lease payment year year year total capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc roche finance report roche group note roche group consolidated financial statement goodwill goodwill movement carry value asset millions chf january lonza singapore acquisition marcadia acquisition business combination impairment charge currency translation effect december allocate follow cashgenerating unit pharmaceutical division roche pharmaceutical chugai total pharmaceutical division diagnostic division diabetes care professional diagnostic molecular diagnostic apply science tissue diagnostic trategic goodwill hold divisional level allocate business area total diagnostic division accumulate impairment loss goodwill goodwill arise investment associate classify investment associate note goodwill impairment testing pharmaceutical division division subdivision cashgenerate unit test goodwill chugai recoverable base fair value cost sell determined reference publicly quote share price chugai share roche pharmaceutical recoverable impairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year cash flow projection extend management recent business plan discount rate base rate derive capital asset pricing model datum swiss capital market include swiss federal government twentyyear bond swiss market index weight average tax rate calculation management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year estimate tissue diagnostic business area project year management believe reflect longterm nature business cash flow projection extend management recent business plan discount rate base rate derive capital asset pricing model datum swiss capital market include swiss federal government twentyyear bond swiss market index weight average tax rate calculation management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january lonza singapore acquisition business combination addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group roche finance report roche group note roche group consolidate financial statement product product intangible marketing technology intangible available intangible intangible use use use use total year end december january marcadia acquisition business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group significant intangible asset december millions chf operate net book remain segment value amortisation period product intangible use tanox acquisition roche pharmaceutical year chugai acquisition chugai year corangeboehringer mannheim acquisition diagnostic year igen acquisition diagnostic year ventana acquisition diagnostic year product intangible available use intermune alliance roche pharmaceutical ventana acquisition diagnostic classification amortisation impairment expense millions chf amortisation impairment amortisation impairment cost sale pharmaceutical diagnostic marketing distribution diagnostic research development pharmaceutical diagnostic general administration pharmaceutical total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful life impairment intangible asset impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment roche pharmaceutical operating segment record impairment charge million swiss franc diagnostic operating segment record impairment charge million swiss franc record roche pharmaceutical operating segment impairment charge million swiss franc record operational excellence programme note programme division carry comprehensive portfolio review decide discontinue certain activity research early development addition certain product development activity discontinue transfer roche site party result decision intangible asset carry value million swiss franc fully write apart operational excellence programme impairment charge million swiss franc record pharmaceutical division respect product intangible available use follow primarily recent clinical datum portfolio prioritisation decision relate certain project alliance partner acquire business combination asset concern amortise fully write charge charge million swiss franc record result portfolio prioritisation decision project acquire previous business combination asset concern amortise write recoverable value million swiss franc base value use calculation discount rate reversal previously record impairment loss million swiss franc record follow late clinical datum assessment project concern diagnostic operating segment impairment charge million swiss franc record respect intangible asset use follow regular updating division business plan technology assessment second half asset concern write recoverable million swiss franc base value use calculation discount rate roche pharmaceutical operating segment record impairment charge million swiss franc diagnostic operating segment record impairment charge million swiss franc roche pharmaceutical operating segment impairment charge million swiss franc record related pharmaceutical division reorganisation note integration programme include prioritise project shared portfolio asset concern fully write charge impairment charge million swiss franc record respect product intangible available use follow recent clinical datum portfolio prioritisation decision relate certain project alliance partner acquire business combination asset concern amortise write recoverable million swiss franc base value use calculation discount rate addition impairment charge million swiss franc record relate intangible asset use follow regular updating division business plan technology assessment second half asset write recoverable million swiss franc base value use calculation discount rate roche finance report roche group note roche group consolidate financial statement diagnostic operating segment impairment charge million swiss franc record respect intangible asset use follow regular updating division business plan technology assessment second half asset write recoverable million swiss franc base value use calculation discount rate intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december carry value asset pharmaceutical division million swiss franc approximately represent project potential decision point month certain circumstance lead impairment inherent uncertainty research development process asset particularly risk impairment project question result commercialise product potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure risk adjust meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total associate group investment associate account equity method goodwill arise investment associate classify investment associate investments associate millions chf share net income carry value total investment associate group significant investment associate material transaction group associate additional information associate give note financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset longterm employee benefit total longterm asset financial longterm asset hold strategic purpose classify noncurrent available forsale investment mainly equity investment primarily investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably carry value equity investment hold cost million swiss franc million swiss franc million swiss franc loan receivable comprise loan party term year inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory expense relate inventory expense cost sale total million swiss franc million swiss franc roche finance report roche group note roche group consolidated financial statement account receivable account receivable million chf trade account receivable note receivable allowance doubtful account chargeback allowance total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc billion swiss franc allowance doubtful account receivable movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december expense relate bad debt expense marketing distribution total million swiss franc million swiss franc significant concentration trade receivables counterparty credit risk describe note current asset current asset millions chf accrue interest income derivative financial instrument restrict cash total financial current asset prepaid expense total nonfinancial current asset total current asset derivative financial instrument asset primarily relate hedge nonus dollardenominated bond note issue finance genentech transaction decline compare december mainly strengthen dollar compare euro offset foreign currency transaction gain nonus dollardenominate bond note note marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss heldfortrade investment bond debenture total financial asset fairvaluethroughprofitorloss heldtomaturity financial asset money market instrument time account month total heldtomaturity financial asset availableforsale financial asset share bond debenture money market instrument time account month investment total availableforsale financial asset total marketable security marketable security hold fund management purpose classify current primarily denominate swiss franc investment hold strategic purpose classify noncurrent note heldfortrade investment hold genentech sell share consist primarily readily saleable equity security bond debenture carry value contract maturity debt security show roche finance report roche group note roche group consolidate financial statement bond debenture millions chf contract maturity year year year total bond debenture money market instrument contract mature year december cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent account payable account payable million chf trade account payable taxis payable dividend payable account payable total account payable accrue current liability accrue liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability derivative financial instrument group use derivative financial instrument risk management activity discuss note derivative financial instrument carry fair value method determine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk manage derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe roche finance report roche group note roche group consolidate financial statement cash flow hedge group issue bond note finance genentech transaction note bond note denominate euros sterling group enter crosscurrency swap hedge foreign exchange interest rate risk cash flow hedge qualify hedge accounting december instrument designate qualify hedge accounting record asset fair value million swiss franc asset million swiss franc ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table decline expect cash flow strong swiss franc euro dollar pound sterling expect cash flow qualify cash flow hedge millions chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total undiscounted cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity decline expect cash flow strong swiss franc euro dollar pound sterling expect cash flow qualify cash flow hedge impact profit loss million chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total change hedge reserve equity show note fair value hedge december group hedge fixedterm debt instrument interest rate swap instrument designate qualified fair value hedge record balance sheet december asset fair value million swiss franc instrument expire july underlie bond redeem loss million swiss franc record interest rate swap loss million swiss franc fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure group enter forward contract designate qualify fair value hedge december instrument record liability fair value million swiss franc asset million swiss franc loss million swiss franc record forward contract loss million swiss franc result forward contract offset change fair value hedge equity investment group use derivative designate qualify hedge relationship manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forward contract option roche finance report roche group note roche group consolidate financial statement provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise year unwind discount business combination currency translation effect december current portion noncurrent portion total provision year end december january additional provision create unused amount reverse utilise year unwind discount business combination acquire company contingent consideration currency translation effect december current portion noncurrent portion total provision expect outflow resource year year year year total provision legal provision legal provision consist number separate legal matter include claim arise trade group company majority cash outflow matter expect occur year dependent development litigation significant provision discount time value money material environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict estimate timing cash outflow show table significant provision discount time value money material restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain global basis show table provision discount time value money material matter employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past performance show table significant provision discount time value money material provision provision relate sale return provision group company fit category timing cash outflow nature uncertain good estimate show table provision discount time value money material matter contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note pharmaceutical legal case accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action united states relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder december hlr defend approximately action bring federal state court united states personal injury allegedly result use accutane action allege ibd result accutane use june hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product united states roche finance report roche group note roche group consolidate financial statement action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation united states district court middle district florida tampa division july district court grant summary judgment favour hlr lead federal ibd case plaintiff appeal august ruling affirm united states court appeal eleventh circuit october district court grant summary judgment favour hlr federal ibd case plaintiff appeal november ruling affirm united states court appeal eleventh circuit recently file matter remain pende action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess total compensatory damage total million dollar verdict reverse appeal retrial result verdict favour plaintiff assess total compensatory damage million dollar hlr currently process posttrial briefing second verdict reverse appeal retrial schedule additional plaintiff add trial hlr appeal verdict superior court new jersey appellate division involve plaintiff trial involve plaintiff schedule february october jury circuit court escambia county florida return verdict favour plaintiff assess total compensatory damage million dollar subsequently reduce million dollars court company october district court appeal state florida reverse enter judgment hlr supreme court florida decline review plaintiff appeal additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim boniva hlr roche affiliate name defendant numerous legal action united states relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause follow condition osteonecrosis jaw onj atypical femoral fracture severe bone pain december hlr defend approximately action bring federal state court state new jersey new york california personal injury allegedly result use boniva boniva case early discovery stage litigation trial date set individual trial result depend variety factor include unique particular case hlr name roche affiliate intend vigorously defend matter outcome matter determine time cabilly patent centocor inc file patent lawsuit genentech city hope national medical center city hope district court central district california lawsuit relate patent cabilly patent coowne genentech city hope cabilly patent expire relate method genentech certain antibody antibody fragment cell dna method genentech license cabilly patent company derive significant royalty licence lawsuit seek declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringement regard certain centocor product august genentech centocor enter settlement agreement resolve lawsuit certain additional patent issue agreement effective april regard royalty centocor agree pay license cabilly patent matter finally resolve october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk file patent lawsuit genentech city hope district court southern district florida lawsuit relate cabilly patent seek declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringement regard certain gsk product december genentech file motion dismiss alternative transfer central district california gsk dismiss florida lawsuit entirety february file related action day northern district california genentech file motion transfer central district california answer counterclaim gsk march april genentech motion transfer grant october court enter order relate claim construction matter include set markman hearing date february outcome matter determine time litigation june ubaldo bao martinez file lawsuit porrio town council genentech espaa contentious administrative court number pontevedra spain lawsuit challenge town council decision grant license genentech espaa construction operation warehouse biopharmaceutical manufacturing facility porrio spain january administrative court rule favour bao claim lawsuit order closing demolition facility subject certain legal proceeding february genentech espaa town council file appeals administrative court decision high court galicia spain march genentech receive notice prevail bao appeal decision revoke january ruling entirety october genentech receive subpoena united states department justice request document relate promotion rituxan genentech cooperate government associate investigation previously investigation civil criminal nature genentech inform august criminal prosecutor handle matter government decline prosecute genentech criminally connection investigation civil matter ongoing counsel genentech continue discussion government representative status investigation genentech view matter include potential resolution october government notify genentech decide civil claim genentech government investigation initiate complaint file seal district court eastern district pennsylvania individual plaintiff complaint unseal december currently basis civil litigation plaintiff roche holdings inc genentech discovery matter ongoing group intend vigorously defend outcome civil litigation determine time hlr roche laboratories inc rli genentech approximately brand generic pharmaceutical company name defendant legal action united states relate pricing pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresented report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend action file follow states alabama mississippi new jersey kansas oklahoma louisiana genentech defend action file state kansas discovery currently pende case hlr rli genentech intend vigorously defend matter outcome matter determine time roche finance report roche group note roche group consolidate financial statement hlr brand pharmaceutical company name defendant legal action united states bring retail pharmacy relate discount practice brand prescription drug bnpd bnpd litigations plaintiff allege deny discount certain prescription drug offer mail order manage care entity denial claim violation robinsonpatman act rpa rpa federal law prohibit unlawful price discrimination addition plaintiff allege defendant conspire refusal offer certain discount conspiracy claim defendant previously settle rpa claim remain litigate december hlr defend approximately bnpd action bring approximately retail pharmacy federal state court united states discovery currently pende case hlr currently schedule trial bnpd matter hlr intends vigorously defend outcome matter determined time november novartis vaccines diagnostic inc chiron affiliate novartis file lawsuit trimeris inc roche group company hoffmannla roche inc hoffmannla roche ltd roche laboratories inc roche colorado corp district court eastern district texas complaint seek injunction damage manufacture sale roche antiaid drug fuzeon united states novartis allege activity infringe claim patent september matter settle roche trimeris take royaltybearing license novartis patent june august september genentech name defendant intermune inc chief executive officer scott harkonen separate classaction complaint file district court northern district california behalf plaintiff allegedly pay purchase price product license genentech connectic corporation subsequently assign intermune genentech respond complaint motion dismiss matter grant april plaintiff file amend complaint include state law claim genentech respond complaint motion dismiss hear september court grant genentech motion dismiss respect claim leave plaintiff replead specific claim california unfair competition law plaintiff file amend class action complaint december naming genentech defendant claim unfair competition law false advertising law consumer remedy law consumer protection law unjust enrichment genentech seek dismissal amend complaint september court enter order grant genentech motion dismiss claim prejudice plaintiff file appeal district court rule united states court appeals ninth circuit briefing appeal ongoing outcome matter determined time october genentech biogen idec inc file complaint sanofiaventis deutschland gmbh sanofi sanofiaventis llc sanofiaventis inc northern district california seek declaratory judgement certain genentech product include rituxan infringe sanofis patent declaratory judgement patent invalid october sanofi file suit genentech biogen idec eastern district texas lufkin division claim rituxan genentech product infringe patent sanofi bring claim preliminary permanent injunction compensatory exemplary damage relief genentech challenge venue texas case opinion federal circuit court appeals texas california case consolidated northern district california district court issue claim construction order june sanofi file motion reconsideration deny genentech biogen idec file motion summary judgment sanofi oppose rule motion issue discovery consolidated matter ongoing addition october hoechst gmbh file icc international court arbitration paris request arbitration genentech relate terminate agreement hoechst predecessor genentech pertain patent relate patent outside united states hoechst seek payment royaltie sale genentech product damage breach contract relief icc arbitration hearing hold august september postheare brief file ruling expect half outcome matter determined time genentech file patent lawsuit university pennsylvania district court northern district california lawsuit relate united states patent seek declaratory judgment patent noninfringement invalidity regard patent july university counterclaimed genentech infringement patent seek unspecified damage base sale herceptin genentech file answer august case management conference hold august markman hearing currently schedule march discovery matter ongoing outcome matter determined time august pdl biopharma pdl file complaint genentech nevada state court seek judicial declaration concern genentech obligation pay royalty certain exus sale herceptin avastin xolair lucentis agreement party september pdl file amend complaint assert additional claim genentech include breach contract breach imply covenant good faith fair dealing pdl assert new claim roche novartis intentional interference contractual relation addition declaratory relief pdl seek monetary damage include liquidate punitive damage november genentech roche file motion dismiss failure state claim roche file additional motion dismiss lack personal jurisdiction outcome matter determined time september gsk genentech file patent lawsuit case gsk roche holding ltd district court district delaware northern district california respectively lawsuit concern gsk patent nos gsk assert claim genentech roche allege infringement patent certain therapeutic antibody product complaint specifically refer herceptin lawsuit genentech seek judicial declaration noninfringement certain genentech product delaware action november genentech file motion dismiss failure state claim motion transfer case california roche file motion dismiss lack personal jurisdiction join genentech motion event personal jurisdiction motion deny motion currently pende california action december court enter order stay california action pende resolution delaware court genentechs motion transfer outcome matter determine time roche finance report roche group note roche group consolidate financial statement noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt gain loss redemption repurchase bond note net amortisation debt discount gain loss financial liability fairvaluethroughprofitorloss net foreign currency transaction gain loss net currency translation effect december consist bond note commercial paper amount bank financial institution genentech leasing obligation finance lease obligation borrowing total debt report longterm debt shortterm debt total debt fair value bond note billion swiss franc billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc billion swiss franc calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollardenominated note float rate month libor note february principal billion dollar note february principal million dollar dollardenominated note fix rate note march principal billion dollar note march principal billion dollar note march principal billion dollar note march principal billion dollar european medium term note programme float rate month euribor note march principal billion euro european medium term note programme fix rate note march principal billion euro note march principal billion pound sterling note march principal billion euro note march principal billion euro note august principal million pound sterling swiss franc bond bond march principal billion swiss franc bond march principal billion swiss franc dollar bond chameleon july principal million dollar genentech senior note senior note july principal million dollar senior note july principal billion dollar senior note july principal million dollar total principal billion dollar note billion dollar redeem march follow group resolution early redeem note roche finance report roche group note roche group consolidate financial statement bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond sterling note total unamortised discount fair value option group apply fair value option outstanding debt instrument group apply fair value hedge accounting past debt instrument european medium term note programme euro bond chameleon dollar bond rodeo swiss franc bond instrument fully redeem date fair value option treatment base elimination accounting mismatch recognise hedging swap report fair value hedge bond report amortise cost issuance new bond note new bond note issue issuance new bond note group finance genentech transaction note combination group fund debt security commercial paper group raise net proceed approximately billion swiss franc series debt offering describe newly issue debt senior unsecured guarantee roche holding ltd dollardenominated note february group complete offer dollardenominate note qualified institutional buyer united states rule person person outside united states regulation securities act group receive approximately billion dollar aggregate net proceed issuance sale fix float rate note march group complete offer dollardenominate note rule securities act roche receive approximately billion dollar aggregate net proceed issuance sale fix rate note term proceed note follow issuance dollardenominated note principal net proceed usd million chf million float rate note float rate note fix rate note fix rate note fix rate note fix rate note fix rate note total european medium term note programme march group issue euro sterling denominate fix float rate note term proceed note follow issuance european medium term note principal net proceed eur millions gbp millions chf million float rate eur note fix rate eur note fix rate gbp note fix rate eur note fix rate eur note total subsequent debt issuance proceed note swap dollar result financial statement note economic characteristic equivalent dollardenominate note swiss francdenominate bond note march group complete offer swiss francdenominate fixedrate bond term proceed bond follow issuance swiss francdenominate bond principal net proceed chf millions chf million fix rate bond fix rate bond fix rate bond total subsequent debt issuance proceed swiss francdenominate bond swap dollar result financial statement bond economic characteristic equivalent dollardenominate bond cash inflow issuance bond note millions chf dollardenominated note european medium term note programme euro sterlingdenominate note swiss francdenominate note total cash inflow issuance bond note redemption repurchase bond note redemption dollardenominated note date february group redeem note principal billion dollar original issue plus accrue original issue discount oid effective interest rate note months libor plus cash outflow million swiss franc gain loss record redemption redemption european medium term note programme note date march group redeem note principal billion euro original issue plus accrue original issue discount oid effective interest rate note month euribor plus plus include hedge cash outflow million swiss franc gain loss record redemption roche finance report roche group note roche group consolidate financial statement redemption genentech senior note date july group redeem note principal million dollar original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record redemption early redemption dollardenominated note june group resolve exercise option redemption dollardenominate fix rate note march principal billion dollars group redeem note september equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal effective interest rate note redemption cash outflow million swiss franc plus accrued interest loss redemption million swiss franc record financing cost note december group resolve exercise option redemption portion dollardenominate fix rate note march group redeem billion dollar total principal billion dollar note march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal treasury rate determine independent investment banker business day precede redemption cash outflow approximately million dollar plus accrue interest expect redemption group revise carrying value note account change amount timing estimate cash flow revise carrying value note december million dollar million swiss franc increase carry value million dollar million swiss franc record financing cost note loss redemption effective interest rate note redemption repurchase bond note redemption chameleon dollar bond group redeem bond remain outstanding principal value million dollar date july original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record income statement redemption redemption repurchase dollardenominate note group redeem note principal value million dollar date september original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record income statement redemption addition group repurchase float rate note principal value million dollar original date february date open market purchase effective interest rate bond month libor plus cash outflow million swiss franc loss million swiss franc record income statement repurchase redemption swiss francdenominate note group redeem note principal value million swiss franc date september original issue plus accrue original issue discount oid effective interest rate bond include associate hedge instrument cash outflow million swiss franc gain loss record income statement redemption cash outflow redemption repurchase bond note millions chf dollardenominated note european medium term note programme eurodenominate note genentech senior note chameleon dollar bond swiss francdenominate note total cash outflow redemption repurchase bond note collateral arrangement collateral agreement enter derivative counterpartie currency swap mitigate counterparty risk fair value derivative instrument move mainly strong dollar compare euro total billion swiss franc cash collateral deliver group billion swiss franc deliver group collateral deliver recorded decrease cash correspond decrease accrue liability carry value accrue liability respect agreement billion swiss franc december accrue liability billion swiss franc realise loss derivative billion swiss franc realise gain billion swiss franc relate mainly hedge nonus dollar denominate bond note commercial paper genentech commercial paper program october genentech establish commercial paper program issue billion dollar unsecured commercial paper note december unsecured commercial paper note principal million dollar outstanding month group fully redeem note maturity principal value genentech terminate commercial paper program amount outstanding december roche holdings inc commercial paper program march roche holdings inc establish commercial paper program issue billion dollar unsecured commercial paper note guarantee roche holding ltd commit credit line billion euro million dollar available backstop line maturity note program exceed day date issuance december unsecured commercial paper note principal million dollar average interest rate outstanding amount date january movement commercial paper obligation millions chf january net cash proceed payment genentech commercial paper program roche holdings inc commercial paper program total net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency notably taiwanese dollar average interest rate average interest rate balance primarily denominate chinese renminbi repayment date year million swiss franc million swiss franc year roche finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement transfer initial carrying value hedge item income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment noncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend pay equity compensation plan net transaction equity instrument chugai share repurchase change ownership interest subsidiary genentech memory change noncontrolle interest december amount transfer income statement losse million swiss franc report royalty operate income gain million swiss franc financial income change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign peration exchange difference noncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend pay equity compensation plan net transaction equity instrument change noncontrolle interest movement december amount transfer income statement gain million swiss franc report royalty operate income loss million swiss franc financial income group complete purchase noncontrolle interest genentech effective march describe note base revise international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report roche group note roche group consolidate financial statement share capital december authorise issue share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share describe note base information supply group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security approve result total distribution shareholder million swiss franc subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security december december millions millions nonvoting equity security derivative instrument total equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number nonvoting equity security strike price market value millions maturity chf chf billion nonvoting equity security derivative instrument feb sep total nonvoting equity security derivative instrument hold group potential conversion obligation arise roche option plan roche stocksettle stock appreciation right roche restrict stock unit plan note mainly consist option exercisable time maturity group hold share reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share non vote equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf roche finance report roche group note roche group consolidate financial statement dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise employee stock option plan exercise outstanding vested employee stock option dilutive effect exercise outstanding vested chugai prior genentech transaction genentech employee stock option dilutive effect net income chugai genentech positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding genentech chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement genentech chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income memory acquisition dividend pay noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity instrument chugai share repurchase change ownership interest subsidiary genentech memory change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest noncontrolle interest equity contribution million swiss franc zero roche finance report roche group note roche group consolidated financial statement statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense associate financial income financing cost income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment intangible asset impairment property plant equipment operating expense define benefit postemployment plan operating expense equitysettle equity compensation plan net income expense provision bad debt expense inventory writedown adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity significant noncash transaction significant noncash transaction total purchase consideration million dollar lonza singapore million dollar million swiss franc noncash settlement loan previously genentech lonza note information risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management specifically describe detail financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai roche finance report roche group note roche group consolidate financial statement carry value fair value financial asset millions chf carry value asset class available fvtplaheld hold loan line item note forsale trading maturity receivables total fair value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total fairvaluethroughprofitorloss follow implementation amendment ifrs financial instrument disclosure publish march group establish fair value hierarchy reflect significance input make fair value measurement fair value hierarchy include follow level level quote price active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture share derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture share derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total availableforsale investment exclude equity security hold cost million swiss franc million swiss franc carry fair value note december level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument unquoted share december level financial asset consist auctionrate student loan security security value base brokerprovide valuation model approximate fair value sell par value significant transfer level level vice versa roche finance report roche group note roche group consolidate financial statement change fair value level financial asset millions chf january impairment charge valuation gain loss take equity gain loss recognise income statement sale currency translation difference december credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset trade receivables subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective management trade receivables sustain growth profitability group optimise asset utilisation whilst maintain risk acceptable level note significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie additionally group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold loan receivables december group combine trade account receivable balance national wholesale distributor amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss franc represent group consolidated trade account receivable billion swiss franc represent nature geographical location trade receivables overdue counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total cash marketable security subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution group receive zero coupon greek government bond settlement overdue receivables allocate bbbrange rating analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivative group sign net collateral agreement isda international swap derivative association master agreement respective counterpartie order mitigate counterparty risk derivative position group enter derivative contract party hedge foreign exchange risk arise bond note issue group affiliate roche holdings inc currencie dollar total exposure hedge issuance bond note approximately billion swiss franc note fair value derivative instrument move weak dollar net cash collateral billion swiss franc deliver group december group return billion swiss franc strengthen dollar euro pound sterle overdue asset financial asset past impair total billion swiss franc billion swiss franc analysis overdue impair financial asset class millions chf total overdue month month month month year year end december loan receivables year end december loan receivables begin increase financial difficulty certain southern european country particularly greece group lead supplier greek healthcare sector trade receivables greek public customer second half group accept offer greek government settle large part overdue trade receivables zero coupon government bond redeemable government bond receive late december group expect receive remain government bond half group carefully monitor situation assess option manage counterparty exposure december financial asset term renegotiate roche finance report roche group note roche group consolidate financial statement liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time group liquidity report senior management monthly basis roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement addition group unused committed credit line financial institution total billion swiss franc billion swiss franc decline undiscounted financial liability show table mainly debt repayment interest pay currency translation effect strong swiss franc euro dollar pound sterle contractual maturity analysis financial liability millions chf total month month month year year year year year year end december total debt trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability year end december total debt trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability total debt table show undiscounted cash flow carry value consolidate balance sheet reflect discount cash flow market risk market risk arise change market price group financial asset financial liability market risk affect group financial result value group equity group use valueatrisk var measure impact market risk financial instrument roche define var limit manage market risk var datum report monthly basis indicate value range give financial instrument fluctuate preset probability result movement market price var statistical measure implicitly assume value change recent past indicative value change future var figure represent actual expect loss possible worstcase loss state period var figure calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate long hold period increase probability high value change lead increase var figure actual future gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include effect change credit spread market risk financial instrument millions chf december december var foreign exchange component var interest rate component var price component diversification var total market risk december total var financial asset liabilitie million swiss franc december million swiss franc interest rate var decrease million swiss franc reflect age debt repayment debt high duration fix income asset hold issue debt hold amortise cost interest rate var sole metric economic fair value change impact carry value profit loss group foreign exchange var remain stable price risk arise mainly movement price equity security decline equity security holding reduce december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration foreign exchange risk group operate world expose movement foreign currency affect group financial result value group equity foreign exchange risk arise local currency pay receive transaction denominate foreign currency vary change exchange rate transaction exposure foreign currency denominate financial statement group foreign subsidiary vary consolidation swiss francdenominate group financial statement translation exposure objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group currently hedge translation exposure financial instrument group monitor transaction exposure daily basis net foreign exchange result correspond var parameter report monthly basis group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate roche finance report roche group note roche group consolidate financial statement interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity change interest rate cause variation interest income expense addition affect market value certain financial asset liability hedge instrument primary objective group interest rate management protect net interest result interest rate exposure correspond var parameter report monthly basis group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure price risk price risk arise mainly movement price equity security december group hold equity security market value billion swiss franc billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration nature business biotechnology company expose great equity volatility general stock market fluctuation group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment equity price risk report var figure monthly basis senior management impairment financial asset impairment loan receivables mainly increase expect nonrecoverability trade receivable note impairment loss asset class millions chf loan receivables availableforsale financial asset share investment debt security total impairment loss capital group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event group complete purchase noncontrolle interest genentech effective march describe note base revise international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy capital monitor basis capitalisation calculate debt plus equity include noncontrolle interest report senior management group regular internal management reporting group capitalisation show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine local management relate party control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise december vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri maja oeri jrg duschmal lukas duschmal group hold share precede year represents issue share figure include share pooled voting right hold outside group individual member group andr hoffmann andreas oeri members board director roche holding ltd hoffmann receive remuneration total swiss franc swiss francs oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate key management personnel member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total remuneration board director exclude chairman total million swiss franc million swiss franc roche finance report roche group note roche group consolidate financial statement chairman board director member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee oday soriot include table calendar year join cec remuneration chairman board director member corporate executive committee millions chf salary include bonus expense special stock award social security cost pension postemployment benefit equity compensation plan employee benefit total purpose remuneration disclosure value equity compensation plan include special stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include financial statement roche holding ltd basel page disclosure value equity compensation plan include special stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration chairman board director member corporate executive committee ifrs basis table deduct special stock award ifrs basis equity compensation plan ifrs basis add special stock award swiss legal basis equity compensation plan swiss legal basis total remuneration chairman board director member corporate executive committee swiss legal basis chairman board director member corporate executive committee special stock awards chairman board director member corporate executive committee grant special stock award lieu cashsettle bonus financial year award roche longterm member corporate executive committee grant stocksettle stock appreciation right ssar roche option plan rop restricted stock unit rsu award ssar rop rsu award roche connect contribution pay group respect chairman board director member corporate executive committee total million swiss franc million swiss franc roche performance share plan member corporate executive committee target award cycle awards cycle award result zero nonvoting equity security depend achievement performance target transaction member corporate executive committee pension tax consulting service total million swiss franc pay group corporate executive committee member million swiss franc member postemployment benefit plan transaction group postemployment define benefit plan employee group describe note subsidiary associate divestment subsidiary effective august group sell wholly own subsidiary lakeside mxico lakeside million swiss franc cash gain loss divestment subsidiary millions chf consideration net asset dispose property plant equipment cash net asset accumulate currency translation adjustment gain loss divestment total gain loss divestment report general administration expense segment result roche pharmaceutical operating segment net cash inflow divestment million swiss franc roche finance report roche group note roche group consolidate financial statement list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share isin genussschein market capitalisation chf japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy nonliste company share capital equity interest country company city millions argentina producto roche qumica industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur belgium roche brussels eur roche diagnostic belgium brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico farmacuticos paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john cad chile roche chile limitada santiago chile clp china roche china hold shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica roche servicios heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican republic producto roche dominicana santo domingo dop ecuador roche ecuador quito usd salvador productos roche salvador san salvador svc estonia roche eesti tallinn eek finland roche diagnostic espoo eur roche espoo eur france roche diagnostic france sas meylan eur roche sas neuillysurseine eur ventana medical systems illkirch eur share capital equity interest country company city millions germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche innovatis bielefeld eur roche kulmbach gmbh kulmbach eur roche pharma grenzachwyhlen eur swisslab gmbh berlin eur greece roche hellas athens eur roche diagnostic hellas athens eur guatemala producto roche guatemala guatemala gtq honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche product india pvt ltd mumbai inr indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd petach tikva il italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd kuala lumpur myr mexico producto roche mexico city mxn roche servicios mxico mexico city mxn morocco roche casablanca mad netherlands roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama producto roche panam panama city pab producto roche interamericana panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru producto roche qumica farmacutica lima pen philippine roche philippines inc makati php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions spain andreu roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland disetronic handel burgdorf chf disetronic holding burgdorf chf hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabete care burgdorf chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche glycart schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united kingdom pirame limited berkshire gbp roche diagnostic ltd lewes gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd alios biopharma inc south san francisco usd bioveris corporation gaithersburg usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd marcadia biotech inc wilmington usd memory pharmaceuticals corp montvale usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche diagnostic operation inc indianapoli usd roche holdings inc wilmington usd roche insulin delivery systems inc fisher usd roche laboratories inc nutley usd roche madison inc madison usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc palo alto usd spring bioscience corp fremont usd therapeutic human polyclonals inc palo alto usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche caracas vef share capital local currency unit roche group report roche management internal control financial report roche finance report report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page franz humer erich hunziker chairman board director chief financial officer deputy head corporate executive committee basel january roche finance report roche group report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany consolidated financial statement roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flow statement change equity note page year end december board director responsibility board director responsible preparation fair presentation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement maintain internal control system relevant preparation fair presentation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgment include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation fair presentation consolidate financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg john morris franois rouiller license audit expert license audit expert auditor charge basel january roche finance report roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg john morris franois rouiller basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting dividend propose board director standard apply retrospectively statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting dividend propose board director standard apply retrospectively roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information base members december comparative information restate include new member fiveyear period roche finance report roche group multiyear overview supplementary information core result ep information group basic diluted earning share information give note consolidated financial statement page group expand presentation core result previously core ep show income statement group operating result division show ifrs core basis allow transparent assessment actual result underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring cost note exclude amortisation impairment intangible asset note exclude acquisition accounting onetime impact alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environment expense financial review exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note material onetime treasury item major debt restructuring settlement pension plan currently exclude global issue outside healthcare sector group control currently exclude core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table avoid doublecounting amount show global restructure exclude item operational excellence programme include adjustment column impairment intangible asset total million swiss franc note additional commentary adjustment item give financial review core result reconciliation million chf alliance normali global intangible business legal sation restruc amorti intangible combi environ ecp tax ifrs ture sation impairment nation mental benefit core sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation million chf alliance normali global intangible business legal sation restruc amorti intangible combi environ ecp tax ifrs ture sation impairment nation mental benefit core sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche finance report roche group multiyear overview supplementary information divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ ifrs ture sation impairment nation mental core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ ifrs ture sation impairment nation mental core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit core eps core net income chf million core net income attributable roche shareholder increase noncontrolle interest share core net income assume outstanding genentech chugai stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share core earning share dilute chf roche finance report roche group multiyear overview supplementary information supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment intangible asset total adjustment add xpense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct net cash flow equity compensation plan utilisation provision proceed disposal total operating profit cash adjustment ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche group roche security roche finance report roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate change ratio adr effective january change ratio adr effective january roche finance report roche group roche security number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number nonvoting equity security genussscheine hold yearend total issue datum share nonvoting equity security chf earning dilute equity attributable roche shareholder dividend stock price share open high low yearend stock price nonvoting equity security genussschein open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange rog bloomberg rog rhhby reuters ros rogvx rhhbypk roche holding ltd basel financial statement roche finance report roche holding ltd basel financial statement income statement millions chf year end december income income participation interest income loan group company interest investment income guarantee fee income group company income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year roche finance report roche holding ltd basel financial statement balance sheet millions chf december december noncurrent asset participation longterm loan longterm loan group company total noncurrent asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company liabilitie total current liability total liability total equity liability pro memoria nonvoting equity security nominal value roche holding ltd basel note financial statement roche finance report note financial statement summary significant accounting policy basis preparation financial statement financial statement roche holding ltd basel prepare accordance provision swiss law participation major participation company list note roche group consolidate financial statement valuation method translation foreign currency marketable security report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate roche finance report roche holding ltd basel note financial statement movement recognise amount millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay december contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december billion swiss franc billion swiss franc primarily relate additional bond note issue group company finance genentech transaction guarantee company describe note roche group consolidated financial statement page significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company share shareholder group pool voting right comprise december vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri maja oeri jrg duschmal lukas duschmala share participation novartis ltd basel include affiliate thereofb information supply shareholder figure share include share pooled voting right hold outside group individual member group figure december supply novartis ltd basel risk management detailed disclosure risk management require swiss law include roche group consolidated financial statement page board executive remuneration board director member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director thousands chf gehrig hoffmann baschera bell brabeckletmathe burns ljr vink frey julius levinson oeri ruttenstorfer teltschik weder mauro total remuneration board director remuneration levinson include payment consult work board membership genentech total thousand swiss franc chairman board directors franz humer receive remuneration show table remuneration chairman board director thousands chf annual salary include bonus expense special stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total roche finance report roche holding ltd basel note financial statement corporate executive committee member corporate executive committee cec roche holding ltd receive remuneration indirect benefit participate certain equity compensation plan show table group ceo severin schwan member corporate executive committee high total remuneration remuneration disclose new member corporate executive committee oday soriot include calendar year join cec remuneration member corporate executive committee thousands chf total cec schwan total cec schwan annual salary include bonus expense special stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total special stock award chairman board director member corporate executive committee grant total special stock awards chairman board director receive award members cec receive total award award grant schwan fair value award employee calculate base fair value nonvoting equity security genussscheine grant date chf chf discount account period block year year award employer contribution social security scheme pension plan group pay social insurance contribution respect remuneration pay contribution pension post employment benefit plan chairman board director member corporate executive committee equity compensation plan chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition award disclose note consolidated financial statement fair value consolidated financial statement represent cost company grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition purpose remuneration disclosure value calculate base fair value employee receive take account preliminary assessment complete performance condition chairman board director member corporate executive committee eligible participate roche connect programme enable employee regular deduction salary purchase nonvoting equity security group contribute programme allow employee purchase nonvoting equity security discount usually member corporate executive committee grant stocksettle stock appreciation right ssar individual award relate show table fair value award employee swiss franc calculate blackschole formula assume hold maturity deduct average twoyear vest period member corporate executive committee member senior management participate roche performance share plan psp group overlapping threeyear psp target award threeyear cycle define begin cycle award consider form employee remuneration equal annual amount threeyear cycle award result zero nonvoting equity security genussscheine depend achievement performance target discretion board director individual award relate show table number award calculate follow psp end cycle performance target achieve accordingly participant receive originally target nonvoting equity security genussscheine psp nonvoting equity security genussschein award psp nonvoting equity security genussschein award result allocation multiply nonvoting equity security genussschein price december swiss franc fair value remuneration receive employee remuneration equity compensation plan thousand chf roche connect ssar awards psp award employer ssar ssar psp psp psp psp total contribution number fair value number number number fair value fair value total cec schwan total remuneration corporate executive committee equity compensation plan million swiss franc million swiss franc attributable schwan member corporate executive committee high total remuneration employee benefit include tax advisory cost incidental benefit include remuneration schwan hunziker burns prof knowle serve chugai board director special payment keller swiss franc year service group transaction member corporate executive committee pension tax consulting service total million swiss franc pay group corporate executive committee member million swiss franc member board executive shareholding board director director andr hoffmann andreas oeri member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table roche finance report roche holding ltd basel note financial statement shareholding member board director nonvoting equity security share genussscheine humer gehrig hoffmann baschera bell brabeckletmathe burn ljr vink frey julius levinson oeri ruttenstorfer teltschik weder mauro total include share hold shareholder group pool voting right equity compensation award roche option plan ssar roche performance share plan hoffmann enter option agreement ubs roche nonvoting equity security period august august hoffmann oeri hold ubs longshort certificate roche bearer share versus roche nonvoting equity security rog vink hold roche american depositary receipt adrs close relative julius hold roche nonvoting equity security genussscheine humer hold rogtpk trackerplus certificate zrcher kantonalbank underlie roche nonvoting equity secu ritie rog corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security genussscheine show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ayyoubi burn hunziker keller jkc knowle oday schwiezer soriot total equity compensation award roche option plan ssar roche performance share plan close relative schwan hold roche nonvoting equity security genussscheine close relative keller hold roche nonvoting equity security genussscheine december chairman board director burns members corporate executive committee hold stocksettle stock appreciation right ssar issue roche option plan award issue show table award hold humer current chairman board director burns current member board director issue previous capacity member corporate executive committee option entitle holder purchase roche nonvoting equity security genussschein specify strike price term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report include business report annual report page roche option plan ssar award hold december year issue total schwan ayyoubi hunziker keller oday soriot total cec humer burn total strike price chf expiry date feb feb jan feb feb feb feb soriots award include award strike price chf expire january december members corporate executive committee show table burns award hold psp award psp performance cycle award hold burns current member board director issue previous capacity member corporate executive committee term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report page business report annual report award result zero nonvoting equity security genussscheine depend achievement performance target discretion board director end cycle performance target achieve accordingly participant receive originally target nonvoting equity security genussscheine total target number award outstanding cycle december show table roche finance report roche holding ltd basel note financial statement roche performance share plan award hold december psp psp schwan ayyoubi hunziker keller oday soriot total cec allocation date feb feb december chairman board director member corporate executive committee time hold total stocksettle stock appreciation right roche option plan award outstanding total award grant roche performance share plan roche holding ltd basel appropriation available earning roche finance report appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year transfer free reserve total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche finance report roche holding ltd basel report statutory auditor financial statement report statutory auditor financial statement report statutory auditor financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany financial statement roche holding ltd comprise income statement balance sheet note page year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgment include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg john morris franois rouiller license audit expert license audit expert auditor charge basel january publish cautionary statement forwardlooke hoffmannla roche ltd tatements basel switzerland annual report contain certain forwardlooking tel statement forwardlooke statement identi fie word believe expect anticipate fax project intend seek estimate future similar expression discussion thing medium office strategy goal plan intention factor group communication cause actual result differ materially future basel switzerland reflect forwardlooke statement contain tel annual report price product fax initiative competitor legislative regulatory devel opment economic condition delay inability obtain regulatory approval bring product market investor relation fluctuation currency exchange rate general basel switzerland financial market condition uncertaintie discovery tel development marketing new product new use fax exist product include limitation negative result clinical trial research project unexpected effect world wide web pipeline market product increase government wwwrochecom pricing pressure interruption production loss inability obtain adequate protection intellectual property right litigation loss key executive order publication employee adverse publicity news tel coverage fax email baselwebmasterrochecom statement earning share growth profit forecast interpret mean annual general meeting roche earning earning share march subsequent period necessarily match exceed historical publish earning earning share roche trademark mention enjoy legal protection roche finance report publish german english case doubt difference interpretation english version shall prevail german text print nonchlorine bleach fsccertified paper roche annual report issue hoffmannla roche ltd basel group communicationsfhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom